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A B S T R A C T
Estradiol, either from peripheral or central origin, activates multiple molecular neuroprotective and neuror-
eparative responses that, being mediated by estrogen receptors or by estrogen receptor independent mechan-
isms, are initiated at the membrane, the cytoplasm or the cell nucleus of neural cells. Estrogen-dependent sig-
naling regulates a variety of cellular events, such as intracellular Ca2+ levels, mitochondrial respiratory capacity,
ATP production, mitochondrial membrane potential, autophagy and apoptosis. In turn, these molecular and
cellular actions of estradiol are integrated by neurons and non-neuronal cells to generate different tissue pro-
tective responses, decreasing blood-brain barrier permeability, oxidative stress, neuroinflammation and ex-
citotoxicity and promoting synaptic plasticity, axonal growth, neurogenesis, remyelination and neuror-
egeneration. Recent findings indicate that the neuroprotective and neuroreparative actions of estradiol are
different in males and females and further research is necessary to fully elucidate the causes for this sex dif-
ference.
1. Introduction
As homeostatic regulators, hormones contribute to preserve a
healthy body function under changing developmental and environ-
mental conditions. Thus, in the brain, hormones maintain neural tissue
homeostasis by regulating blood flow, the access of nutrients and the
physiological activity of the different cell types that constitute the
nervous system. This protective action of hormones is also operative
when the body is affected by diseases and injuries. Estradiol is a good
example of a hormonal signal that impacts on brain function and be-
havior, regulating neural development and plasticity and the activity of
neuronal circuits involved in different endocrine, homeostatic and be-
havioral tasks. In addition, estradiol protects brain function from al-
terations caused by disease and/or aging. Neuroprotective actions of
estradiol were suggested by early studies showing an improvement in
cognitive measures of women that received short-term estrogen therapy
after bilateral oophorectomy, compared to placebo treated women
(Sherwin, 1988). Since then, basic research has shown that estradiol is
neuroprotective in cellular and/or animal models of stroke, perinatal
asphyxia-hypoxia, Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal
cord injury, diabetic encephalopathy, hypertensive encephalopathy and
cognitive decline, among others (see Tables 1 and 2 and the following
sections).
Additional studies in women that received estrogen therapy in the
early postmenopausal stage have confirmed that the hormone decreases
the risk of cognitive decline and dementia (Scott et al., 2012; Rocca
et al., 2014; Engler-Chiurazzi et al., 2017), in agreement with the ori-
ginal observations (Sherwin, 1988). However, they also revealed that
estrogen therapy initiated several years after menopause increases the
risk of dementia, indicating that there is a critical window of oppor-
tunity for estrogen neuroprotection, depending on age and time of in-
itiation of the treatment after menopause. This critical period for es-
trogen therapy has been confirmed in animal studies, which have
demonstrated that both long-term estrogen deprivation and aging im-
pair the neuroprotective actions of estradiol, in association with a down
regulation of the expression of estrogen receptors (ERs) in the brain
(Scott et al., 2012). Other factors may also contribute to the loss of
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Table 1
Examples of neuroprotective mechanisms of estradiol in in vitro models.
Injury model Cell type Protective mechanisms Selected references
Hypoxia Primary cortical astrocytes from neonatal
12 day-old mouse pups and microglial BV-2 cell
line
Estradiol reduces IL1B in BV-2 microglia cell line, but not in
primary astrocytes, under hypoxia. Induction of NLRP3 protein
levels by hypoxia is attenuated when BV-2 cells are treated with
estradiol.
Slowik et al. (2018)
Oxygen/glucose deprivation E19 Primary Hippocampal neurons GPER1 knockdown attenuates estradiol protective effects,
while GPER1 overexpression preserves estradiol benefits in
primary hippocampal neurons. Estradiol treatment increasea
MTT activity, loweres Annexin-V levels and attenuates LDH
release. These effects were further potentiated when
overexpressing GPER1.
Zhao et al. (2016)
Oxygen/glucose deprivation (OGD)/
reperfusion
Primary cortical astrocytes Estradiol pretreatment improves cell viability after 6 h OGD/
24 h reperfusion, attenuates apoptotic cell ratio, LDH release
and oxidative radical generation and protects mitochondrial
function. The same outcome is observed when cells are treated
with PPT, an ERα agonist.
Guo et al. (2012)
bEnd.3 endothelial cells Estradiol enhances the integrity of tight junctions in endothelial
cells submitted to OGD.
Na et al. (2015)
Potassium superoxide or oxygen/
glucose deprivation
Brain slices from C57BL/6J mice Brain slices treated with estradiol have increased superoxide
dismutase 1 (SOD1) and attenuated oxidative stress and DNA
damage.
Rao et al. (2011)
Glucose deprivation T98G cells (astroglioma) Estradiol increases the expression of neuroglobin in glucose
deprived cells and this effect is mimicked when cells are treated
with the ERβ agonist DPN. Blockage of neuroglobin reduces
estradiol protection in T98G cells.
Avila-Rodriguez
et al. (2014, 2016)
β-amyloid Cholinergic cell line Estradiol activates Raf-1/MEK/ERK1/2 to promote cell survival
in septal derived cholinergic murine cell line (SN56).
Guerra et al. (2004)
Primary rat cerebrocortical neurons Estradiol attenuates JNK activation (decreases JNK
phosphorylation) induced by Aβ25–35 in neuronal cultures,
and this is accompanied by attenuated mitochondrial
cytochrome c and Smac release and the upregulation of Bcl2
family proteins and the inhibition of proapoptotic signaling.
Yao et al. (2007)
BV-2 microglial cells and primary neuronal cells Estradiol induces an attenuation of iNOS, COX-2 and Iba1 levels
in BV-2 cells treated with β-amyloid, while it reduces NFkB
DNA binding activity, cleaved caspase 3 and Bax proteins (pro-
apoptotic proteins) in primary neurons stimulated with β-
amyloid.
Yun et al. (2018)
Human fetal olfactory neuroepithelium Cells pretreated with IGF-1 and estradiol show increased
survival and attenuated oxidative stress, and these protective
effects are partly lost when blocking estrogen receptors.
Protective actions of estradiol are dampened upon blockage of
IGF-1R, suggesting a possible crosstalk of estradiol and IGF-1
protective signaling. As a downregulated gene in Alzheimer’s
Disease, seladin-1 might, at least in part, mediate the
neuroprotection by estradiol.
Luciani et al. (2008,
2012)
Hydrogen peroxide (H2O2) exposure Cortical neurons Estradiol acting on GPER increases phosphoERK1/2 and Bcl-2
and reduces oxidative damage by H2O2.
Liu et al. (2011)
SK-N-BE cells
Striatal neurons
MCF-7 cells
Estradiol favors the formation of huntingtin-neuroglobin
complex in mitochondria and neuroglobin translocation to
mitochondria depends upon non-mutated huntingtin. Mutated
huntingtin impairs estradiol-induced regulation of neuroglobin
and dampens its induced anti-apoptotic actions. Co-stimulation
of cells with BDNF and estradiol further increases neuroglobin
upregulation.
Nuzzo et al. (2017)
Human retinal pigment epithelial cells (ARPE-
19)
Estradiol increases autophagy in human retinal pigment
epithelial cells exposed to hydrogen peroxide.
Wei et al. (2018)
6-hydroxydopamine (6-OHDA) Organotypic mesencephalic cultures from 7 day-
old Wistar rat pups
Estradiol induces activation of MAPK signaling and
upregulation of Bcl-2 expression in dopaminergic neurons.
Wang et al. (2011)
Lipopolysaccharide Mouse primary cortical astrocyte cultures Estradiol preserves neuroglobin levels in astrocytes stimulated
with LPS. Blockade of estrogen receptors abolishes estradiol
actions on neuroglobin levels. DPN mimics estradiol effects on
neuroglobin expression, suggesting an involvement of ERβ.
De Marinis et al.
(2013)
Estradiol reduces IL6 and IP-10 mRNA and protein levels in
astrocytes stimulated with LPS.
Cerciat et al. (2010)
Palmitic acid Primary astrocytes derived from male and
female 2 day-old Wistar rat pups
Estradiol increases Hsp70 and IL-10 in astrocytes from male
and female pups. Estradiol attenuates pJNK, and TNFα in male
astrocytes, but not females, demonstrating a sex dimorphic
effect.
Frago et al. (2017)
None 1-day-old rat primary astrocytes Estradiol increases GLT1 and GLAST in primary astrocytes, thus
decreasing extracellular glutamate levels. The effect is
mediated by GPER.
Lee et al. (2012) and
Karki et al. (2014)
Glutamate toxicity Primary cortical neurons Glutamate induces a 50% reduction in phosphatase PP1 levels
and estradiol prevents the significant drop in PP1, PP2A, and
calcineurin protein levels. Estradiol reduces the decreased PP2
activity induced by glutamate in cortical neurons
Yi and Simpkins
(2008)
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neuroprotective actions of estradiol with aging or after a long period of
estrogen deprivation (Azcoitia et al., 2011). Therefore, a better un-
derstanding on the molecular and cellular mechanisms of estradiol is
still necessary to develop improved estrogenic neuroprotective thera-
pies.
Recent papers have reviewed the neuroprotective actions of sex
hormones and related synthetic steroids in different central nervous
system (CNS) pathologies (Elkabes and Nicot, 2014; Engler-Chiurazzi
et al., 2017: Baez-Jurado et al., 2018; Céspedes Rubio et al., 2018;
Bourque et al., 2019; Kulkarni et al., 2019; Sohrabji et al., 2019), in-
cluding some of the specific molecular neuroprotective mechanisms
activated by estradiol (Arevalo et al., 2015; Sohrabji, 2015; Labandeira-
Garcia et al., 2016; Zup and Madden, 2016; Marin and Diaz, 2018;
Thakkar et al., 2018) and the role played by glial cells on the neuro-
protective mechanisms of the hormone (Karki et al., 2014; Acaz-
Fonseca et al., 2016; Kipp et al., 2016; Martin-Jimenez et al., 2019).
Another important issue that has been considered in recent years is the
neuroprotective role of estradiol locally synthesized in the CNS
(Pedersen et al., 2018; Brocca and Garcia-Segura, 2018). However, it is
still necessary to integrate the molecular mechanisms activated by es-
tradiol from central and peripheral origin with the subcellular, cellular
and tissue events involved in the neuroprotective and reparative actions
of the hormone. In addition, most of the studies dealing with the mo-
lecular and cellular mechanisms that mediate neuroprotection by es-
tradiol have been conducted in either male or female animals or in
unsexed culture systems. However, the limited available evidence
suggests that estradiol has not the same neuroprotective actions in
males and females. Therefore, it is important to consider the variable
sex in the analysis of the neuroprotective mechanisms of estradiol. In
consequence, our aim here is to integrate the reported molecular me-
chanisms activated by estradiol with the subcellular, cellular and tissue
events that participate in the protective and reparative actions of the
hormone and to discuss the role of sex differences in these mechanisms.
2. Molecular mechanism involved in the neuroprotective actions
of estradiol
2.1. Nuclear- and membrane-initiated estrogen signaling
As in other body organs, estradiol signaling in the nervous system is
mediated by classical ERs, ERα and ERβ, located in the cell nucleus, by
ERs located in the plasma membrane or the cytoplasm, including ERα,
ERβ and G protein-coupled estrogen receptor-1 (GPER) and by ER in-
dependent signaling mechanisms. ERs located in the plasma membrane
or the cytoplasm modify the activation of different kinases and phos-
phatases and other signaling molecules in the nervous system and in-
teract with the signaling pathways of membrane receptors, such as
insulin-like growth factor-1 (IGF-1), Wnt and Notch signaling (Fig. 1).
In parallel to membrane and cytoplasmic actions, or as a consequence
of the activation of membrane or cytoplasm initiated signaling, estra-
diol regulates transcriptional activity in neurons, glial cells and other
cellular elements of the nervous system through nuclear ERs and
through other transcription factors, such as nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB), signal transducer and ac-
tivation of transcription (STAT3) or cAMP response element binding
protein (CREB) (Fig. 1). Additional molecules, such as microRNAs
(miRNAs), also participate in the transcriptional regulation exerted by
estradiol in the brain (Fig. 1).
The transcriptional activity of estradiol results in the regulation of
the expression of several neurotrophic and neuroprotective factors,
such as neuroglobin, huntingtin, cocaine-and amphetamine-regulated
transcript (CART), IGF-1, brain derived neurotrophic factor (BDNF),
hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth
factor (VEGF), transforming growth factor α (TGFα) and β (TGFβ) and
glial derived neurotrophic factor (GDNF). Estradiol also regulates in
neural cells the expression of molecules regulating apoptosis and en-
zymes involved in cholesterol synthesis or in endocannabinoid meta-
bolism. All these molecular mechanisms regulated by estradiol (Fig. 1),
which are exerted in parallel in different neural cell types, participate in
the protective actions of the hormone in the nervous system and are
reviewed in the following subsections.
2.1.1. Estrogen receptors α and β
ERα and ERβ are encoded by two different genes, but present some
overlapping sequence homology. They are transcription factors that,
after being activated by estradiol, directly regulate transcription of
target genes by binding to estrogen response elements in their pro-
moters. Unliganded ERα and ERβ are also activated by protein-kinase
signaling pathways and regulate transcription in absence of estradiol
activation (Marino et al., 2006). In addition, ERα and ERβ regulate
transcription by interacting with other transcription factors, such as
activator protein 1 (AP-1), STAT3, activation transcription factor 2
(ATF-2), transcription factor Sp1 and NFκB (Marino et al., 2006).
Furthermore, ERα and ERβ are localized in the cytoplasm or the
plasma membrane, where they interact with the kinases of different
membrane-initiated signaling pathways. In the plasma membrane, ERs
are localized in specific domains, the lipid rafts, in which different re-
ceptors and signaling proteins are integrated (Marin et al., 2013). This
allows the interaction of ERs with other neuroprotective signaling
pathways (Marin et al., 2013). Membrane-initiated estrogen signaling is
also mediated by the interaction of membrane ERs with G-protein
coupled receptors, such as group I mGluRs or group II mGluRs, asso-
ciated to Gq and Gi/o, respectively, or by GPER (see Section 2.1.2).
The role of ERα in the mediation of the neuroprotective actions of
Table 1 (continued)
Injury model Cell type Protective mechanisms Selected references
Primary neurons from embryonic day 18
Sprague–Dawley rat fetuses
Estradiol attenuates neuronal death by excitotoxicity and
apoptotic mechanisms by regulating intracellular calcium
levels.
Zhao and Brinton
et al. (2007)
Estradiol inhibits L-type Ca2+ channel and Ca2+ influx. Sribnick et al. (2009)
AMPA toxicity and serum
deprivation
Primary astrocytes from spinal cord of 1–3-day-
old Sprague–Dawley rats and Cultures of
enriched spinal cord motoneurons
Astrocytic GDNF release, induced by pretreatment with
estradiol, protects spinal cord motoneurons from AMPA-
induced death.
Platania et al. (2005)
Serum deprivation E15 Primary neuronal cultures from fetal rat
hypothalamus
Either IGF-1 or estradiol increase the number of MAP-2
immunoreactive neurons and neuritic processes. Blockade of
IGF-1 dampens neuroprotective actions of estradiol and
inhibition of estrogen receptors blocks IGF-1 protective effects,
suggesting a crosstalk between both signaling mechanisms.
Duenas et al. (1996)
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Table 2
Examples of neuroprotective mechanisms of estradiol in in vivo models.
Animal/Injury model CNS region Protective mechanisms Selected references
3-months old female Wistar albino rats subject
to ovariectomy
Hippocampus and dorsal
root ganglion neurons
Estradiol inhibits calcium influx, thus attenuating the rise in
intracellular calcium, by actions on TRPM2, TRPV1 and TRPA1.
Yazğan et al. (2017)
2–3months old and 16months old Sprague-
Dawley female rats subject to
ovariectomy
Hippocampus Estradiol and activation of G-protein coupled receptor exhibits
antidepressant and anxiolytic effects in ovariectomized aged rats.
Activation of GPER, using G-1, improves mitochondrial function in the
aged hippocampus by preserving mitochondrial membrane potential
and antioxidant activity. Activation of GPER augments Bcl-2 and UCP2
levels in the hippocampus of aged animals.
Wang et al. (2018)
4-week old Wistar albino female rats ip
injected with kainic acid
Hippocampus: Hilar
interneurons
Estradiol protects hilar interneurons in kainic acid injected rats. Co-
administration of estradiol with kainic acid improves neuronal
survival, a similar outcome when animals are injected with IGF-1. The
inhibition of ERs prevented the neuroprotective action of IGF-1 and the
inhibition of IGF-1 receptor prevented the neuroprotective action of
estradiol.
Azcoitia et al. (1998,
1999)
Ovariectomized Sprague Dawley rats subject
to transient middle cerebral artery
occlusion (MCAO)
Ipsi and contralateral
ischemic brain hemispheres
Estradiol prevents the decrease in phosphatases PP1, PP2A and
calcineurin.
Yi and Simpkins (2008)
Adult male Sprague–Dawley rats subject to
MCAO
Hippocampus and cortex Estradiol increases neurogenesis, HIF-1α and VEGF in the
subventricular zone.
Zheng et al. (2013)
Adult male and female rats exposed to
bilateral common artery occlusion or
MCAO
Hippocampus Estradiol increases synaptic proteins such as synaptophysin and PSD95
and also the number of dendrites in both CA1 hippocampal region in
male and cerebral cortex of ovariectomized female rats.
Zhu et al. (2017) and
Khan et al. (2015)
8–10weeks Female mice subject to MCAO Cerebral cortex Targeting miR181a protects female mice from MCAO, and these effects
were mediated by ERα.
Stary et al. (2017)
Treatment with estradiol induces upregulation of cocaine- and
amphetamine-regulated transcript (CART) in the cerebral cortex of
ischemic animals. Upregulation of CART by estradiol reduces cell death
and DNA damage by a mechanism mediated through CREB.
Xu et al. (2006)
6-weeks old female Sprague Dawley rats
subject to global ischemia
Hippocampus Global ischemia induces an increased phosphorylation of STAT3 in
CA1, and estradiol further augments its phosphorylation levels in the
postischemic CA1. Blockage of STAT3 dampens estradiol-induced
protection of CA1 neurons following global ischemia. Silencing of
surviving, an antiapoptotic gene regulated by STAT3, abolishes the
neuroprotective action of estradiol.
Sehara et al. (2013)
Female Sprague Dawley rats subject to global
ischemia
Endogenous and exogenous estradiol protect the CA1 neurons in rats
following global ischemia. Estradiol increases phosphorylation of
CREB, CaMKII and MAPK.
Raval et al. (2009)
Estradiol increases the number of NeuN+ neurons and the levels of
pAkt and pERK and decreased p-JNK levels, in CA1. Akt or ERK
inhibitors prevent the neuroprotective action of estradiol. pCREB
induction by estradiol was followed by increased BDNF levels in CA1.
Yang et al. (2010)
3-months-old female Sprague Dawley rats
subject to global ischemia
Estradiol regulates the activation and morphological changes of Iba-1
positive microglia and induces a more M2-like anti-inflammatory
microglia phenotype in the hippocampus.
Thakkar et al. (2016)
Estradiol attenuates neuronal death and infarct in ischemic animals
through ERα. These actions of estradiol include reduced superoxide
production, and NADPH oxidase activation possibly by a Rac1
signaling mechanism.
Zhang et al. (2009)
4–6months old C57BL/6 mice subject to
global ischemia
Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), a co-
regulator of ERs, is critical in mediating estradiol extranuclear
protective actions in ischemic animals.
Sareddy et al. (2015)
Perinatal asphyxia in rats CA1 hippocampus Estradiol treated adult animals subject to perinatal asphyxia show an
increase in ERα expression, attenuated anti-apoptotic levels, decreased
dendritic alterations, activation of PI3K/Akt/GSK3β/β-catenin
signaling and an increase in Bcl2/Bax ratio in the hippocampus.
Saraceno et al. (2018)
Traumatic brain injury. 3-months old female
Sprague Dawley rats
Pericontusional area of
cerebral cortex
Estradiol activates ERK and PI3K/AKT and promotes cell survival.
Estradiol induces ERα expression and surviving mRNA and attenuates
caspase 3 activation.
Bao et al. (2011)
Male and female adult zebra finches subject to
penetrating brain injury
Brain Brain injury induces NFkB mRNA levels in both male and female zebra
finches, regardless the sex or time after injury. Treatment with an
aromatase inhibitor (fadrozole) after brain injury induces IkB
expression in male, but not in females, and increases IL-1β and IL-6
expression in both male and females.
Cook et al. (2018)
Wistar albino female and male rats subject to
penetrating brain injury
Cerebral cortex Estradiol and the SERMs raloxifene and tamoxifen attenuate reactive
astroglia and microglia in the cortex of castrated young and aged rats
in comparison to sham animals.
Barreto et al. (2009,
2014)
Estradiol lowers glial scar density nearby the wound. Estradiol restores
monoacylglycerol lipase and N-acyl phosphatidylethanolamine
phospholipase D mRNA levels in the injured cortex. In presence of
estradiol, cannabinoid receptors (CB2) are upregulated in the injured
cortex.
López Rodríguez et al.
(2011)
14-week old male Wistar rats subject to spinal
cord injury
Spinal cord Estradiol improves behavior and attenuates inflammation and
inflammasome parameters in spinal cord injured animals.
Zendedel et al. (2018)
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estradiol in different brain injury models is well established. These in-
clude cellular and animal models of focal and global ischemia (Suzuki
et al., 2009; Zhang et al., 2009, 2017; Guo et al., 2012; Tables 1 and 2),
chronic hypertension (Pietranera et al., 2016), Parkinsońs disease
(Morissette et al., 2008; Al Sweidi et al., 2012), Alzheimer’s disease
(Guerra et al., 2004; Table 1) and multiple sclerosis (J. Feng et al.,
2013; Spence et al., 2013; Table 2; Fig. 2). In addition to its role as
transcription factor, ERα exerts neuroprotective actions by activating
membrane-initiated signaling. In response to estradiol, ERα interacts in
the brain with the p85 subunit of the phosphoinositide 3 (PI3) kinase to
activate the PI3K/Akt neuroprotective signaling pathway (Mendez
et al., 2006; Mannella and Brinton, 2006; Wang et al., 2006). This in-
teraction may happen in the neuronal plasma membrane where ERα
forms a macromolecular complex with caveolin-1 and voltage-depen-
dent anion channel (VDAC) in the lipid rafts (Marin et al., 2013). Es-
tradiol inactivates VDAC through protein kinase A and Src-kinase and
this mechanism may mediate protective actions of the hormone against
β-amyloid-induced neurotoxicity (Marin et al., 2013). One protein in-
teracting with ERα, Src and the p85 subunit of the PI3K is proline-,
glutamic acid- and leucine-rich protein 1 (PELP1) (Sareddy et al., 2015;
Thakkar et al., 2018; Table 2). PELP1 is a multi-domain scaffold protein
and acts as an ER coregulatory factor that facilitates ER-mediated
transcription. Studies from Brann’s laboratory have shown that PELP1
plays a critical role in neuroprotective and anti-inflammatory estradiol
signaling (Sareddy et al., 2015; Thakkar et al., 2018; Table 2).
ERβ also participates in the neuroprotective actions of estradiol
(Fig. 2). This has been demonstrated using ERβ KO mice, for instance in
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse
model of Parkinson’s disease (Al Sweidi et al., 2012). Other studies have
shown the neuroprotective actions of selective ERβ agonists. Thus, the
selective ERβ ligand, AC-186, is neuroprotective in a Parkinson model
induced by 6-hydroxydopamine injections in the substantia nigra in
male rats (McFarland et al., 2013). The selective ERβ agonist diaryl-
propionitrile (DPN) reduces brain damage after transient middle cere-
bral artery occlusion (MCAO) model of stroke (Connell and Saleh,
2011) and after bilateral carotid artery occlusion, a model of global
ischemia (Carswell et al., 2004). The selective ERβ agonist WAY
200,070 is also neuroprotective in transient global cerebral ischemia
(Miller et al., 2005) and the specific ERβ ligand 4-(1-phenyl-cyclo-
hexyl)-phenol (AC-131) has been shown to exert neuroprotective ac-
tions in a model of focal stroke in rats (Madinier et al., 2014). The ERβ
selective agonist DPN is neuroprotective in the hippocampus of chronic
hypertensive rats (Pietranera et al., 2016) and increases GFAP expres-
sion in astrocytes and decreases neuronal apoptosis in co-cultures of
astrocytes and neurons exposed to oxygen glucose deprivation and re-
perfusion (Ma et al., 2016). Protective actions of DPN and other ERβ
ligands, such has indazole-Cl and WAY-202041, have been also char-
acterized in mouse models of multiple sclerosis, where they stimulate
endogenous myelination and functional recovery (Atkinson et al., 2019;
Khalaj et al., 2016; Karim et al., 2018, 2019) (see also Section 4.8).
Furthermore, ERβ expressed in astrocytes mediates the protective effect
of estradiol on neurons exposed to oxygen-glucose deprivation and re-
perfusion (Ma et al., 2016) and ERβ regulates inflammasome activation
and protects from global cerebral ischemia in senescent female rats (de
Rivero-Vaccari et al., 2016).
Table 2 (continued)
Animal/Injury model CNS region Protective mechanisms Selected references
8-weeks old C57BL-6 female mice subject to
MPTP
Ventral midbrain including the
substantia nigra compacta
MPTP treatment augments dopaminergic neuron death, reduced
dopamine and DOPAC levels in the striatum of ovariectomized mice.
Estradiol reduces Rho activity and mRNA levels, as well as Rock II
mRNA in the nigral region of ovariectomized mice. Estradiol action on
reducing RhoA/Rock activity is associated with the blockage of
angiotensin type 1 receptors.
Rodriguez-Perez et al.
(2013)
10–14weeks-old C57Bl/6 male mice subject
to MPTP
Substantia nigra Estradiol increases SOD2 activity and SOD2 immunoreactivity and
reduces nitrotyrosine levels in the substantia nigra. MPTP treatment
reduces Akt/GSK3β phosphorylation and estradiol prevents this
reduction, possibly through activation of ERα.
Tripanichkul et al.
(2013)
Striatum Pre-treatment with estradiol activates increases IGF-1 receptor
expression and PI3K/Akt/GSK3β signaling. Estradiol, or the ERα
agonist PPT, prevents the decrease in Bcl2/Bad ratio, oxidative stress
and dopaminergic loss induced by MPTP in the striatum.
D’Astous et al. (2006)
Adult male Wistar rats subject to intra-striatal
6‐OHDA injection
Estradiol favors the upregulation of GDNF in the substantia nigra, and
this finding is corroborated in neuron-glia cultures.
Campos et al. (2012)
6-weeks old female Sprague Dawley rats or
C57/B6 mice treated with LPS (icv)
Cerebral cortex Estradiol attenuates microglia reactivity and mRNA levels of MCP-1,
MIP-2 and TNF-α in the cerebral cortex of animals treated with LPS.
Vegeto et al. (2006)
9-weeks old female ICR mice infused with
Aβ1-42
Hippocampus -
Astrocytes
Microglia
Estrogen deficiency (ovariectomized mice) leads to increased memory
impairment and Aβ1-42 treated animals presented an augmented
latency in the passive avoidance test. More neuronal death in the CA3,
and higher levels of iNOS, GFAP, Iba1, neprilysin, BACE1, and
amyloidogenesis in the hippocampus of ovariectomized and Aβ1-42
treated animals.
Yun et al. (2018)
Spontaneously hypertensive 5‐months old
male Wistar–Kyoto (WKY) rats
Hippocampus Estradiol upregulates aromatase, increases the number of dendritic
spines in CA1, the number of doublecortin and proliferating cells and
BDNF mRNA levels and reduces astrogliosis in the hippocampus of
hypertensive rats.
Pietranera et al. (2015)
2-months-old female Wistar rats treated with
trimethyltin
Hippocampus Estradiol upregulates genes involved in neuroprotection (Bcl2, Bdnf,
trkB) and synaptogenesis (Cdk5 and Cdh2) in the hippocampus of
trimethyltin-treated animals. Estradiol also upregulates markers of
interneurons (glutamic acid decarboxylase 67, neuropeptide Y and
parvalbumin.
Corvino et al. (2015)
6–7months female SD rats subject to blue
light-emitting diode-induced retinal
degeneration
Retina Pretreatment with estradiol reduces retinal damage by reducing
aopotosis (downregulation of Bax) and increasing autophagy.
Wei et al. (2018)
Female C57BL/6 immunized with myelin
oligodendrocyte glycoprotein
(experimental model of EAE)
Spinal cord Estradiol acting on ERα in astrocytes induces anti-inflammatory and
neuroprotective action in experimental autoimmune encephalomyelitis
(EAE) in vivo model.
Spence et al. (2013)
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2.1.2. GPER
After the identification of GPER as a membrane receptor mediating
the actions of estradiol (Srivastava and Evans, 2013), numerous studies
have examined its role in the neuroprotective mechanisms of the hor-
mone (Tables 1 and 2; Fig. 2). For instance, it has been shown that
GPER mediates protective actions of estradiol in cultured cortical
neurons exposed to oxidative stress (Liu et al., 2011; Table 1), in pri-
mary hippocampal neurons and in rat motoneurons exposed to oxygen-
glucose deprivation (Chen et al., 2015; Zhao et al., 2016; Table 1), in
primary mouse cortical cultures exposed to NMDA (S.B. Liu et al., 2012)
and in dopaminergic neurons of mesencephalic cultures exposed to
MPP(+) (Bessa et al., 2015). Furthermore, GPER mediates the upre-
gulation of the expression of the glutamate transporter GLT-1 and the
uptake of glutamate in astrocytes (Lee et al., 2012; Table 1), which may
decrease excitotoxic neural damage (see Section 4.3).
In vivo studies have shown that the GPER agonist G1 upregulates the
expression of ERα, ERβ and GPER in the hippocampus of aged female
rats and counteracts the effects of aging on anxiety and depressive
behavior in these animals (J. Wang et al., 2018). GPER is also involved
in the neuroprotective actions of estradiol in focal and global ischemia
models in male and female rodents (Zhang et al., 2010, 2018; S.B. Liu
et al., 2011, 2012; Céspedes Rubio et al., 2018). For instance, G1 and
the non-classical ER ligand STX protect against hippocampal neuronal
loss induced by ischemia in middle-aged female rats (Lebesque et al.,
2010). G1 also decreases infarct size after cerebral artery occlusion in
ovariectomized mice (Zhang et al., 2010) and exerts anti-inflammatory
effects in the MCAO mouse model of stroke, reducing infarction volume
and the release of TNF-α, IL-1β, and IL-6 in the ischemic penumbra
(Zhang et al., 2018). GPER is also involved in the neuroprotective ac-
tions of estradiol on traumatic brain injury in adult male rats (Day et al.,
2013) and in the MPTP mouse model of Parkinson’s disease (Bourque
et al., 2015). GPER activation is also neuroprotective in the brain of
ovariectomized aged rats (Wang et al., 2018; Table 2). The neuropro-
tective mechanisms of action of GPER can be integrated in the signaling
of the classical ERs, since it has been shown that ERα requires GPER to
mediate neuroprotective actions of estradiol on dopaminergic neurons
in a mouse model of Parkinson’s disease (Bourque et al., 2015).
2.2. ERK
The mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinases (ERK) signaling pathway has been shown to partici-
pate in the neuroprotective mechanisms of estradiol in numerous ex-
perimental models of neurodegenerative diseases. This signaling
pathway is activated by estradiol and is involved in the protective ac-
tions of the hormone in septal derived cholinergic cells exposed to β-
amyloid (Guerra et al., 2004; Table 1), in hippocampal neurons exposed
to glutamate (Zhao and Brinton, 2007), in cortical neurons exposed to
oxidative damage (Liu et al., 2011), in the hippocampus of male rats
treated with quinolinic acid (Kuroki et al., 2001) and in in vivo ex-
perimental models of brain ischemia (Wang et al., 2006; Zhang et al.,
2008; Yang et al., 2010; Table 2) and traumatic brain injury (Bao et al.,
2011; Table 2), among others. The activation of ERK by estradiol is
associated with the inhibition of neurodegenerative signaling, such as
JNK (see Section 2.4). For instance, in the hippocampus, estradiol
protects CA1 neurons from global ischemia by a mechanism involving
ERK activation and the inhibition of JNK (Yang et al., 2010; Table 2).
Fig. 1. Main molecular components of
neuroprotective estradiol signaling. The
protective signaling mechanism of estradiol
(E2) in the nervous system are initiated by
extranuclear estrogen receptors (exnER)
located in the plasma membrane or the
cytoplasm and by nuclear receptors (nER),
which act as transcription factors. exnERs
modify the activation of different kinases,
such as ERK, PI3K, Akt, GSK3β, AMPK and
JNK, phosphatases, such as PP1, PP2A and
PP2B, and other signaling molecules, such
as β-catenin, mTORC1, RhoA, ROCK and
the ER coactivator PELP1. exnERs also in-
teract with other signaling pathways, such
as IGF-1, Wnt and Notch signaling. In ad-
dition to nERs, other transcription factors,
such as NFκB, STAT3 or CREB, and
microRNAs, such as miR-7-1 and miR-181a,
are involved in the transcriptional regula-
tion induced by estradiol. By the activation
of exnERs and nERs, estradiol regulates in
the brain the transcription of antiapoptotic
molecules, such as Bcl-2 and survivin, the
expression of several neurotrophic and
neuroprotective proteins, such as IGF-1,
BDNF, HIF-1α, VEGF, TGFα, TGFβ, GDNF,
neuroglobin, huntingtin and CART, and the
expression of molecules involved in en-
docannabinoid signaling and metabolism or
in cholesterol synthesis, such as seladin-1.
All these molecular mediators participate in
the neuroprotective actions of estradiol.
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2.3. PI3K/Akt
We have already mentioned (Section 2.1.1) that estradiol induces
the interaction of ERα and the p85 subunit of the PI3K in the brain to
activate the PI3K/Akt signaling pathway (Mendez et al., 2006;
Mannella and Brinton, 2006; Wang et al., 2006). PI3K/Akt signaling is
also activated by estradiol in primary hippocampal neurons through
GPER and the inhibition of Notch signaling (Arevalo et al., 2015) and
by the ERβ ligand DPN in the corpus callosum in vivo, in a mouse model
of multiple sclerosis (Kumar et al., 2013). Since PI3K/Akt activates
survival mechanisms in a variety of cell types, this kinase signaling
pathway may be one of the main mediators of the protective actions of
estradiol in the nervous system. Indeed, activation of PI3K/Akt sig-
naling by estradiol is associated with the neuroprotective actions of the
hormone in the pericontusional region of the cerebral cortex after
traumatic brain injury (Bao et al., 2011; Table 2). PI3K/Akt signaling is
also involved in the neuroprotective actions of the hormone in the
MPTP mouse model of Parkinson’s disease (D’Astous et al., 2006;
Morissette et al., 2008; Al Sweidi et al., 2012; Table 2), in models of
retinal neuron degeneration (Yu et al., 2004), in rat models of global
cerebral ischemia (Wang et al., 2006; Zhang et al., 2008; Yang et al.,
2010; Table 2) and in a rat model of perinatal asphyxia (Saraceno et al.,
2018; Table 2). Furthermore, the PI3K/Akt signaling pathway mediates
the release of the neuroprotective factor TFGβ by astrocytes in response
to estradiol (Dhandapani et al., 2005).
One of the main targets of the neuroprotective mechanisms of es-
tradiol is the regulation of apoptosis (see Section 4.5). Apoptosis is
inhibited by the PI3K/Akt signaling pathway, which may therefore
mediate the anti-apoptotic actions of estradiol. In fact, the involvement
of this pathway in the prevention of apoptosis by estradiol has been
demonstrated in primary cortical neurons exposed to ketamine (R. Li
et al., 2013) or staurosporine (Honda et al., 2001), in retinal cells ex-
posed to oxidative damage (Y. Feng et al., 2013) and in motoneurons
exposed to oxygen glucose deprivation (Chen et al., 2015) or to a
neuroinflammatory challenge (Smith et al., 2009). Furthermore, the
activation of PI3K signaling by estradiol is associated with the
Fig. 2. Role of estrogen recetors in neuroprotection. Selected studies documenting the participation of ERα, ERβ or GPER in the neuroprotective actions of estradiol
or selective ER ligands.
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upregulation of the anti-apoptotic Bcl-2 gene or with the increase in the
ratio of expression of anti-apoptotic and pro-apoptotic genes, such as
Bcl-2/Bax or Bcl-2/Bad ratio, in organotypic mesencephalic cultures
(Wang et al., 2011; Table 1), in the hippocampus of animals exposed to
perinatal asphyxia (Saraceno et al., 2018; Table 2) and in the striatum
in a mouse Parkinson’s disease model (D’Astous et al., 2006; Table 2).
2.4. JNK
In addition to activate neuroprotective kinases, such as PI3K/Akt,
estradiol inhibits the activity of kinases that promote neurodegenera-
tion, such as c-Jun N-terminal kinases (JNKs). JNKs are involved in the
mediation of stress stimuli and the initiation of apoptosis. Its inhibition
by estradiol mediates the neuroprotective action of the hormone in
different brain injury models. Thus, estradiol decreases JNK phos-
phorylation induced by β-amyloid in primary rat cerebrocortical neu-
rons (Yao et al., 2007), in rat neuronal cortical cells exposed to gluta-
mate (Rong et al., 2012), in the brain of neonatal rats exposed to
ethanol (Khan et al., 2018) and in rat models of global cerebral
ischemia (Wang et al., 2006; Zhang et al., 2008; Yang et al., 2010;
Table 2).
In primary rat cortical neurons exposed to β-amyloid toxicity, the
inhibition of JNK by estradiol is associated with the attenuation of
cytochrome c release by the mitochondria and the upregulation of the
expression of the antiapoptotic molecule Bcl-2 (Yao et al., 2007;
Table 1). The inhibition of JNK by estradiol in the rat hippocampus
prevents Wnt/β-catenin signaling antagonist Dickkopf-1 elevation after
global cerebral ischemia (Wang et al., 2006; Zhang et al., 2008). This
enhances neuroprotection mediated by Wnt/β-catenin signaling
pathway (see next section).
2.5. PELP1, Wnt, GSK3β and β-catenin
Downstream of Akt, estradiol regulates the activity of glycogen
synthase kinase 3β (GSK3β) and β-catenin in neurons (Wandosell et al.,
2012; Sareddy et al., 2015; Saraceno et al., 2018; Table 2). Estradiol
treatment results in the activation of Akt, which in turn phosphorylates
and inhibits GSK3β and this results in the stabilization of β-catenin.
This signaling mechanism is involved in the regulation of neuronal
cytoskeleton and neuronal survival and mediates neuroprotective ac-
tions of estradiol. Indeed, the regulation of GSK3β/β-catenin signaling
is associated with the protective effects of the hormone in different
models of neurodegenerative diseases, including Parkinson’s disease,
brain ischemia (D’Astous et al., 2006; Céspedes Rubio et al., 2018; Q.G.
Zhang et al., 2018) and perinatal asphyxia (Saraceno et al., 2018) (see
Table 2). Estradiol regulates GSK3β and β-catenin not only through
PI3K/Akt but also through Wnt signaling (Mendez et al., 2006; Zhang
et al., 2008; Wandosell et al., 2012).
In addition, the ER coregulatory factor PELP1, which is also in-
volved in the neuroprotective mechanisms of estradiol (Sareddy et al.,
2015; Thakkar et al., 2018), interacts with both ERα, PI3K and GSK3β
and increases Wnt/β-catenin signaling (Sareddy et al., 2015). PELP1
modulates GSK3β activity and in turn GSK3β activity modulates PELP1
phosphorylation. Estradiol regulates PELP1 phosphorylation by reg-
ulating GSK3β activity and decreases the interaction of PELP1 and
GSK3β (Sareddy et al., 2015; Table 2). All these findings suggest that
PELP1, GSK3β and β-catenin are involved in the neuroprotective mo-
lecular mechanisms of estradiol.
2.6. mTORC1 and AMPK
Another factor downstream of ERK and PI3K is Mammalian Target
of Rapamycin Complex-1 (mTORC1), a protein complex that activates
protein translation. mTORC1 is regulated by growth factors that acti-
vate the PI3K/Akt signaling pathway, such as IGF-1 and BDNF (Perez-
Alvarez et al., 2018), which are involved in the neuroprotective
mechanisms of estradiol (see Section 2.13). Estradiol activates the
PI3K/Akt/mTORC1 pathway in neurons to promote neuritic growth
and it has been proposed that mTORC1 may participate in the neuro-
protective mechanisms of estradiol after brain ischemia (Perez-Alvarez
et al., 2018) and in the remeyelination induced by the ERβ ligand DPN
in an experimental mouse model of multiple sclerosis (Kumar et al.,
2013). One of the best characterized functions of mTORC1 is to connect
environmental cues, such as nutrient availability, with cellular home-
ostasis, including the inhibition of autophagy. Since the regulation of
autophagy is involved in cell survival mechanisms, it is possible that the
regulation of this cellular process by mTORC1 may contribute to the
promotion of neuronal survival by estradiol. A key metabolic sensor
that regulates mTORC1 and autophagy is AMP-activated protein kinase
(AMPK). Interestingly, estradiol exerts neuroprotective actions in neu-
rons exposed to oxygen-glucose deprivation through the activation of
AMPK (Guo et al., 2017) and the inhibition of autophagy has been
associated with neuroprotective effects of estradiol in animal models of
spinal cord injury (Lin et al., 2016) and cerebral ischemia (Li et al.,
2017). Therefore, the possible interaction of estradiol, AMPK, mTORC1
and autophagy as a mechanism involved in the neuroprotective actions
of estradiol merits to be further explored in detail (see also Section 4.6).
2.7. RhoA/ROCK
Estradiol regulates actin cytoskeleton in many cell types, including
neurons, through the small GTP-binding protein Rho (Ras homolog
gene family, member A (RhoA)/RhoA kinase (ROCK) pathway. This
signaling pathway participates in dendritic spine formation and
memory and is also involved in the anti-inflammatory and neuropro-
tective effects of estradiol in the MPTP model of Parkinson’s disease in
ovariectomized mice (Rodriguez-Perez et al., 2013) and in experimental
autoimmune encephalomyelitis, a rat model of multiple sclerosis (J.
Feng et al., 2013). The inhibition of RhoA/ROCK activity by estradiol is
associated with the blockage of angiotensin (AT) type 1 receptors
(Rodriguez-Perez et al., 2013; Table 2). AT1 receptor activation en-
hances dopaminergic neuronal loss in the nigro-striatal system, while
the inhibition of renin-angiotensin activity and the downregulation of
AT1 receptors by estradiol are associated with anti-inflammatory and
neuroprotective actions of the hormone in both male and female rats of
the 6-hydroxidopamine model of Parkinsońs disease (Rodriguez-Perez
et al., 2013; Table 2).
2.8. Protein phosphatases
The mediation of protein kinases in the neuroprotective actions of
estradiol suggest that protein phosphatases, such as protein phospha-
tase (PP) 1, PP2A, PP2B, calcineurin and PTEN may also be involved in
the neuroprotective mechanisms of the hormone. Indeed, it has been
shown that estradiol prevents the decrease in the expression of PP1,
PP2A and PP2B induced by transient middle cerebral artery occlusion
in the injured brain tissue and by glutamate in primary rat cortical
neurons (Yi and Simpkins, 2008; Tables 1 and 2). Furthermore, the
inhibition of PP1, PP2A and calcineurin has been shown to partially
impair hormonal protection against glutamate-induced excitotoxicity in
vitro (Yi and Simpkins, 2008). On the other hand, estradiol has also
been shown to down-regulate the expression of PTEN, an inhibitor of
PI3K/Akt, allowing the phosphorylation and activation of Akt and the
prevention of apoptosis in motoneurons exposed to a neuroin-
flammatory challenge (Smith et al., 2009). These findings suggest that
an adequate function of protein phosphatases is necessary for the ac-
tivation of the neuroprotective mechanisms of estradiol.
2.9. NFκB
NFκB is a transcription factor that participates in numerous cell
functions, including the regulation of the expression of molecules
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involved in inflammation, such cytokines and chemokines, and apop-
tosis. It is regulated by estradiol and plays a central role in the hor-
monal control of neuroinflammation (see Section 4.7). The regulation
of NFκB activation by estradiol is one of the neuroprotective mechan-
isms activated by the hormone in animal models of neurodegenerative
diseases, such as traumatic brain injury, cerebral ischemia and Alz-
heimer’s disease (Wen et al., 2004; Cook et al., 2018; Yun et al., 2018;
Table 2). In these models, estradiol deficiency increases brain damage
in parallel with an increased NFκB activation (Cook et al., 2018; Yun
et al., 2018; Table 2).
The main cellular populations that participate in the regulation of
the inflammatory response in the brain are microglia (see Section 5.5).
In these glial cells, as well as in macrophages, estradiol decreases NFκB
activation induced by LPS or other proinflammatory signals by a me-
chanism involving ERα and PI3K activation (Vegeto et al., 2006; Khan
et al., 2018). Estrogenic inhibition of NFκB activation and nuclear
translocation (Cerciat et al., 2010) or inhibition of NFκB-mediated
transcription (Giraud et al., 2010) has also been observed in astrocytes,
another glial cell involved in the control of neuroinflammation in the
brain (see Section 5.3). However, the effect of estradiol on NFκB acti-
vation is not restricted to glial cells, because the hormone decreases
also NFκB activation in neurons (F. Liu et al., 2012; Yun et al., 2018)
and in cerebral blood vessel endothelial cells (Ospina et al., 2004).
2.10. STAt3
Estradiol inhibits neuronal apoptosis by the regulation of the ac-
tivity of STAT3, a transcription factor that is under the control of the
PI3K signaling pathway. STAT3 induces the transcription of anti-
apoptotic genes, such as Bcl-2 and survivin (see Section 4.5) and is
involved in the neuroprotective mechanisms of estradiol (Dziennis
et al., 2007; Zhang et al., 2008; Sehara et al., 2013; Table 2). Thus, it
has been shown that estradiol regulates the phosphorylation of STAT3
in the brain of ovariectomized female rats after middle cerebral artery
occlusion or global cerebral ischemia and that STAT3 is necessary for
the neuroprotective action of the hormone (Dziennis et al., 2007;
Sehara et al., 2013). For instance, blockage of STAT3 dampens the
neuroprotective action of estradiol in CA1 neurons after global ischemia
(Sehara et al., 2013; Table 2).
2.11. CREB and CART
The ERK signaling pathway activates the transcription factor CREB,
which is known to mediate numerous physiological mechanisms in
response to estradiol. CREB is also involved in the neuroprotective ac-
tions of the hormone. For instance, estradiol increases CREB expression
(Raval et al., 2009; Table 2) and prevents the decrease in CREB phos-
phorylation induced by global cerebral ischemia in female rats
(Lebesgue et al., 2009; Yang et al., 2010; Table 2). One of the genes
regulated by CREB and that is highly induced by estradiol in the cer-
ebral cortex of ovariectomized female rats exposed to middle cerebral
artery occlusion is CART (Xu et al., 2006; Table 2). In primary cortical
neurons a CART-neutralizing antibody prevented the protective action
of estradiol against oxygen-glucose deprivation (Xu et al., 2006). Thus,
a possible signaling pathway including ERK, CREB and CART may be
involved in the neuroprotective actions of the hormone through mem-
brane ERs.
2.12. MicroRNAs
Non-coding RNAs, including miRNAs, have emerged as a new level
of post-transcriptional regulation. In the brain, miRNAs participate in
the regulation of neurogenesis, neural development, synaptogenesis
and synaptic plasticity and their dysregulation may play a key role in
the pathogenesis of neurodegenerative diseases and affective disorders.
The intercellular transport of miRNAs by extracellular vesicles
represents an additional mechanism for paracrine and endocrine com-
munication and also a promising avenue for the diagnosis of brain al-
terations and for therapeutic interventions.
miRNAs participate in the transcriptional regulation exerted by ERs
in different tissues, including the brain. For instance, the neuroprotec-
tive signaling pathways activated by estradiol in the brain, such as the
PI3K/Akt pathway, are known to regulate the expression of numerous
miRNAs (Recaberren-Leiva and Alarcon, 2018). Thus, in the MCAO
model, it has been shown that estradiol controls the expression of genes
involved in apoptosis and neuroinflammation by the regulation of
miRNAs (Herzoq et al., 2017). In addition, some miRNAs may interfere
with the neuroprotective signaling of estradiol. For instance, miR-7-1
potentiates the neuroprotective effect of the hormone in the prevention
of apoptosis of spinal cord motoneurons exposed to a calcium iono-
phore (Chakrabarti et al., 2014), while the inhibition of miR-181a in-
creases the expression of ERα in female astrocytes, facilitating estradiol
protective actions against focal cerebral ischemia (Stary et al., 2017;
Table 2). Although these studies suggest that miRNAs participate in the
neuroprotective mechanisms of estradiol, further investigation is re-
quired to accurately determine and generalize the role of non-coding
RNAs and extracellular vesicles in the neuroprotective actions of the
hormone in different models of neurodegenerative and affective dis-
orders.
2.13. Neurotrophic factors
The PI3K/Akt signaling pathway mediates the interaction of estra-
diol signaling with the signaling of other neuroprotective factors, such
as insulin-like growth factor 1 (IGF-1) (Mendez et al., 2006). The in-
teraction of the neuroprotective mechanisms of estradiol and IGF-1 has
been identified in hypothalamic rat neurons submitted to serum de-
privation in vitro (Duenas et al., 1996; Table 1) and in human fetal
neuroblasts exposed to β-amyloid (Luciani et al., 2008, 2012; Table 1).
This interaction has been also identified in studies in vivo, in rodent
models of excitotoxicity (Azcoitia et al., 1999; Table 2), Parkinson’s
disease (Quesada et al., 2008; Bourque et al., 2009), experimental
stroke (Sohrabji, 2015) and perinatal asphyxia (Saraceno et al., 2018;
Table 2). In addition, recent findings indicate that estradiol and IGF-1
neuroprotective signaling also interact through GPER in the MPTP
model of Parkinson’s disease (Yuan et al., 2019).
Brain derived neurotrophic factor (BDNF) is involved in numerous
physiological actions of estradiol in the brain and also mediates the
neuroprotective actions of the hormone. For instance, estradiol in-
creases BDNF expression in the hippocampus in rat models of hy-
pertensive encephalopathy (Pietranera et al., 2015, 2016; Table 2) and
BDNF mediates the neuroprotective actions of estradiol against NMDA
induced excitotoxicity in cultured hippocampal slices (Aguirre and
Baudry, 2009) and in animal models of global cerebral ischemia (Yang
et al., 2010; Table 2). Both IGF-1, acting on IGF-1 receptor, and BDNF,
acting on TrkB receptor, activate PI3K/Akt and ERK signaling that, as
mentioned before, mediate numerous neuroprotective actions of es-
tradiol. Thus, estradiol may exert a redundant activation of the neu-
roprotective PI3K/Akt and ERK pathways through IGF-1 and BDNF
(Arevalo et al., 2015).
Other neurotrophic factors that may mediate the neuroprotective
actions of estradiol in the adult rodent brain are HIF-1α, VEGF, TGFα,
TGFβ and GDNF. The expression of HIF-1α and VEGF is increased by
the hormone in the rat brain after permanent focal cerebral ischemia
(Zheng et al., 2013; Table 2). TGFα mediates the upregulation of glu-
tamate transporter GLT-1 induced by the hormone in rat primary as-
trocytes (Lee et al., 2012; Table 1). Thus, by mediation of TGFα, es-
tradiol protects neurons and other neural cells from excitotoxicity, by
decreasing extracellular glutamate levels as a consequence of the in-
creased extracellular glutamate transport by astrocytes (see Section
4.3). TGFβ and GDNF are released by astrocytes in response to estradiol
and mediate neuroprotective effects of the hormone in different cellular
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models. TGFβ protects cortical neurons from β-amyloid toxicity and
other neurotoxic insults (Sortino et al., 2004; Dhandapani et al., 2005),
whereas the release of GDNF by astrocytes in response to estradiol has
been suggested to protect spinal motoneurons from AMPA toxicity
(Platania et al., 2005; Table 1). Furthermore, GDNF has been shown to
be involved in the protective action of estradiol against 6-OHDA toxi-
city in the substantia nigra and in neuron-glia cultures (Campos et al.,
2012; Table 2).
2.14. Seladin-1 and cholesterol
The expression of Selective Alzheimer’s disease indicator-1 (Seladin-
1) gene is strongly reduced in vulnerable brain regions of Alzheimer’s
disease patients. This gene confers resistance against β-amyloid toxicity
and oxidative stress and mediates the protective effect of estradiol in
human fetal neuroepithelial cells exposed to β-amyloid (Luciani et al.,
2008, 2012; Table 1). Seladin-1 gene encodes the enzyme 3-β-hydro-
xysterol delta-24-reductase, which catalyzes the synthesis of cholesterol
from desmosterol. Cholesterol levels are reduced and β-amyloid levels
are increased in the brain of seladin-1 deficient mice, while seladin-1
overexpression increases cholesterol levels and resistance to β-amyloid
toxicity. These findings suggest a possible role of cholesterol in the
neuroprotective actions of estradiol (Luciani et al., 2012). Cholesterol is
necessary for synaptogenesis and may be required for the reparative
effects of estradiol on the damaged synaptic circuits (see Section 4.2). In
addition, an adequate cholesterol and lipid composition in the lipid
rafts is necessary for the interaction of membrane-associated ERs with
other plasma membrane components (Marin et al., 2013). Therefore,
changes in cholesterol levels in the neuronal lipid rafts with aging and
Alzheimer’s disease may impair the neuroprotective signaling of
membrane-associated ERs in the brain.
2.15. Neuroglobin and huntingtin
The oxygen binding protein neuroglobin is a member of the globin
family and has structural similarities to α- and β-chains of hemoglobin
and to myoglobin. Neuroglobin, which is associated with mitochondrial
proteins and inhibits mitochondria-dependent apoptotic signaling, is
expressed in the nervous system and protects brain cells from oxidative
stress, hypoxia/ischemia and mitochondrial dysfunction (Baez et al.,
2016). Estradiol has been shown to induce the expression of neu-
roglobin in neuroblastoma cells, primary hippocampal neurons and
astrocytes by means of both nuclear- and membrane-initiated ERβ
signaling (De Marinis et al., 2013; Avila-Rodriguez et al., 2014, 2016;
Table 1). Estradiol induces the translocation of neuroglobin to the mi-
tochondria, where neuroglobin exerts its antiapoptotic neuroprotective
actions (Nuzzo et al., 2017; Table 1). Furthermore, neuroglobin med-
iates neuroprotective actions of estradiol in neurons and anti-in-
flammatory effects of the hormone in astrocytes (De Marinis et al.,
2013; Avila-Rodriguez et al., 2014, 2016; Table 1).
Neuroglobin interacts with huntingtin in different cell lines, in-
cluding neuronal cells (Nuzzo et al., 2017; Table 1). This interaction
with huntingtin allows the translocation of neuroglobin from the cy-
tosol to the mitochondria (Nuzzo et al., 2017). Both the expression of
huntingtin and the interaction of neuroglobin with huntingtin are sig-
nificantly increased by estradiol (Nuzzo et al., 2017; Table 1). Hun-
tingtin is a well-known protein, since the presence of an abnormal
polyQ expansion in its N-terminal sequence causes the development of
Huntington’s disease. Non-mutated huntingtin participates in numerous
molecular interactions and cellular functions and is necessary for es-
tradiol-induced neuroglobin upregulation and mitochondrial localiza-
tion (Nuzzo et al., 2017). Thus, mutated huntingtin with 111 glutamine
residues in the polyQ region prevents the induction of neuroglobin
expression and mitochondrial localization by estradiol and the anti-
apoptotic effects of the hormone in neuroblastoma cells (Nuzzo et al.,
2017). These findings indicate that huntingtin is necessary for the
neuroprotective action of the estradiol-neuroglobin pathway (Nuzzo
et al., 2017).
2.16. Notch signaling
Notch is a transmembrane receptor involved in cell to cell contact
communication. Notch receptor is activated by transmembrane ligands,
such as Jagged and Delta. The activation of Notch receptor results in the
cleavage of its intracellular domain, which is translocated to the cell
nucleus and regulates the expression of different transcription factors,
such as hairy and enhancer of split (Hes) 1 and 5 (Arevalo et al., 2011).
Estradiol is known to regulate Notch signaling in cancer and en-
dothelial cells (Arevalo et al., 2011). In breast cancer cells, there is a
cross-talk between estrogen and Notch signaling. Thus, Notch regulates
ERα-mediated transcription and in turn estradiol inhibits Notch sig-
naling by an ERα-mediated mechanism (Arevalo et al., 2011). Inter-
actions of estradiol and Notch signaling have been also detected in the
nervous system. In hippocampal slice cultures, estradiol decreases the
levels of the intracellular domain of Notch-1, indicating a reduced ac-
tivity of Notch signaling (Bender et al., 2010). In addition, estradiol
reduces the activity of Notch and the expression of Notch regulated
genes, such as Hes-1, in primary mouse hippocampal neurons (Arevalo
et al., 2011).
One of the functions of Notch signaling in the brain is the regulation
of neuritogenesis. Notch acts as a repressor of neuronal development by
the downregulation of neuritogenic genes, such as the transcription
factor neurogenin 3. In primary hippocampal neurons estradiol upre-
gulates the expression of the neuritogenic gene neurogenin 3 and pro-
motes neuritogenesis and dendritogenesis, via the inhibition of Notch
signaling (Arevalo et al., 2011). This effect of estradiol is mediated by
GPER and the activation of PI3K signaling pathway (Ruiz-Palmero
et al., 2013). Therefore, the regulation of Notch signaling by estradiol
may be relevant for the neuritogenic effects of the hormone for neu-
ronal regeneration after brain injury (see Section 4.2). However, the
role of Notch signaling in the neuroprotective and neuroreparative
mechanism activated by estradiol in animal models of neurodegenera-
tive diseases has not been fully explored yet.
2.17. Endocannabinoids
Endocannabinoids are a family of molecules that are synthesized in
response to physiological stimuli and participate in numerous events in
the nervous system, including the regulation of neural development,
synaptic transmission, synaptic plasticity, behavior and memory. In
addition, the endocannabinoid system maintains brain tissue home-
ostasis under pathological conditions and the levels of en-
docannabinoids and the expression of the enzymes involved in en-
docannabinoid synthesis and metabolism are altered in different models
of brain injury and neurodegeneration. Estradiol regulates and interacts
with the brain endocannabinoid system in the modulation of inhibitory
synaptic transmission under physiological conditions (Tabatadze et al.,
2015) and a few reports suggest that the endocannabinoid system may
participate in the mechanism of neuroprotection elicited by estradiol.
In rats exposed to MCAO, the neuroprotective actions of estradiol
are associated with a decrease in the levels of the endocannabinoid
arachidonoylethanolamide, or anandamide in the striatum (Amantea
et al., 2007). The levels of this endocannabinoid are increased in the
injured tissue, and estradiol prevents this increase. The effect of estra-
diol may be mediated by decreasing the activity of the enzyme N-
acylphosphatidylethanolamide-hydrolyzing phospholipase D (NAPE-
PLD), which synthesizes anandamide, and by increasing the activity of
the enzyme fatty acid amide hydrolase (FAAH), which metabolizes
anandamide in arachidonic acid and ethanolamine. Furthermore, the
neuroprotective action of estradiol, via ERs, is also accompanied by a
reduction in cannabinoid CB1 receptor binding, suggesting a decreased
signaling of endocannabinoids via CB1 receptors (Amantea et al.,
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In a model of traumatic brain injury estradiol reduces gliosis in the
cerebral cortex in parallel with the increase in the expression of the
enzyme monoacylglycerol lipase (MAGL), involved in the metabolism
of 2-arachidonoylglycerol (2-AG), and the expression of the ananda-
mide synthetizing enzyme NAPE-PLD. Furthermore, estradiol increases
the expression of CB2 cannabinoid receptors in the injured cerebral
cortex and both CB1 and CB2 receptor antagonists prevent the anti-
gliotic effect of estradiol after traumatic brain injury (López Rodríguez
et al., 2011; Table 2). All these findings indicate that estradiol affects
endocannabinoid levels and signaling after ischemic and traumatic
brain injuries and suggest that the neuroprotective actions of the hor-
mone, at least in these brain injury models, involve the regulation of the
endocannabinoid system. However, further studies are necessary to
elucidate the precise role of endocannabinoid signaling in the neuro-
protective mechanisms of estradiol.
3. Role of brain derived estradiol in neuroprotection
In addition to be a gonadal hormone, estradiol is locally synthesized
in different body tissues and acts as a local paracrine or autocrine
factor. The enzyme aromatase, which converts testosterone in estradiol,
is expressed in the central nervous system. In the mammalian brain and
under physiological conditions this enzyme is mainly localized in
neurons and participates in the regulation of different brain functions
by the regulation of local estradiol levels in the brain tissue. Thus, brain
aromatase activity has been shown to be implicated in the regulation of
neurogenesis, neuronal differentiation, synaptic function, synaptic
plasticity, pain regulation, locomotor activity, sexual behavior, social
behavior, affective behavior, locomotor activity and cognition, among
other functions (Azcoitia et al., 2018; Brocca and Garcia-Segura, 2018).
In addition, under conditions of brain injury, including traumatic brain
injury, cerebral ischemia or excitotoxicity, the expression of the enzyme
is induced in astrocytes (Garcia-Segura et al., 1999; Saldanha et al.,
2009; Zhang et al., 2014; Pedersen et al., 2018) together with an in-
crease in brain aromatase activity (Garcia-Segura et al., 1999) and brain
estradiol levels (Q.G. Zhang et al., 2014; Mehos et al., 2016).
The induction of aromatase in astrocytes after brain injury is
mediated by acute inflammatory signals and by bone morphogenetic
protein 2 (BMP2) originated in microglia (Duncan and Saldanha, 2011;
Duncan et al., 2013; Pedersen et al., 2018). Moreover, it is associated
with injury-induced glial expression of CREB binding protein CBP
(Klores et al., 2017) and with enhanced NFκB signaling (Klores et al.,
2017; Cook et al., 2018).
Glial aromatase expression after injury probably represents a nat-
ural mechanism of neuroplasticity activated for neuroprotection and
repair (Duncan et al., 2013). Indeed, the inhibition of aromatase ac-
tivity or the silencing of aromatase expression in the brain results in
increasing gliosis, neuroinflammation and damage in the injured neural
tissue (Azcoitia et al., 2001; McCullough et al., 2003; Sierra et al., 2003;
Zhang et al., 2014, 2017), including an increase in apoptotic secondary
neurodegeneration (Saldanha et al., 2009; Wynne et al., 2008; Duncan
et al., 2013) and a reduction in injury-induced neurogenesis and cell
migration (Walters et al., 2011; Duncan et al., 2013).
Aromatase inhibition also prevents the neuroprotective actions of
estradiol precursors, such as testosterone or dehydroepiandrosterone
(Veiga et al., 2003; Juhász-Vedres et al., 2006). The neuroprotective
role of brain estradiol synthesis has been identified in different models
of brain injury, including excitotoxicity (Azcoitia et al., 2001), cere-
bellar ataxia (Sierra et al., 2003), traumatic brain injury (Pedersen
et al., 2018), brain ischemia (McCullough et al., 2003; Zhang et al.,
2014, 2017), Alzheimer’s disease (Yue et al., 2005; Chang et al., 2013)
and Parkinson’s disease (Gillies and McArthur, 2010b).
It is important to mention that in the injured rodent brain aromatase
is not only expressed by astrocytes, but also by neurons and brain en-
dothelial cells. Therefore, a decreased estradiol production by these
cells may contribute to the increased brain damage observed after the
inhibition of aromatase activity or the silencing of aromatase expres-
sion in models of brain injury. Indeed, in some animal models of
chronic neurodegeneration, such as in rat models of hypertensive en-
cephalopathy (Pietranera et al., 2015) or chronic sciatic nerve injury
(Schaeffer et al., 2010), aromatase expression is increased in hippo-
campal neurons and dorsal root ganglion cells and not in astrocytes or
satellite glial cells, respectively. These findings suggest that increased
expression of aromatase in neurons after brain injury may also con-
tribute to neuroprotection.
4. Subcellular, cellular and tissue events involved in the
neuroprotective and reparative actions of estradiol
4.1. Neurogenesis
The actions of estradiol on adult neurogenesis and the regulation of
axonal growth, synaptogenesis, dendritic remodeling and synaptic
plasticity are well documented. These neuroplastic effects of estradiol
are essential for the role that the hormone plays in the maintenance of
adult brain homeostasis, including its effects on neuroendocrine events,
cognition and memory. The regulation of neuroplasticity may also be
involved in the neuroprotective actions of estradiol under pathological
circumstances. Indeed, the signaling pathways and molecules involved
in the neuroprotective actions of estradiol discussed in the previous
sections, such as ERK, PI3K/Akt, Wnt, GSK3β/β-catenin, RhoA/ROCK,
IGF-1, BDNF, neuroglobin and endocannabinoids, are known to be in-
volved in the regulation of neuritogenesis, synaptogenesis and adult
neurogenesis and may therefore participate in the neuro-reparative
processes elicited by the hormone through the enhancement of brain
plasticity.
Although the role of the human adult hippocampal neurogenesis is
still controversial, the existence of adult neurogenesis in the rodent
brain and its regulation by estradiol is well established. The best
characterized neurogenic niches in the adult rodent brain are the sub-
granular cell layer (SGL) in the dentate gyrus and the subventricular
zone (SVZ) of the lateral ventricles. Other neurogenic niches have been
identified in the olfactory bulbs, the cerebral cortex, the striatum, the
hypothalamus and the cerebellum. In addition to physiological basal
level of neurogenesis, neurodegenerative stimuli induce its activation in
the SGL and the SVZ (Yu et al., 2016). Injury-induced neurogenesis has
probably a reparative role (Wu et al., 2017) and, therefore, the reg-
ulation of injury-induced neurogenesis by estradiol may participate in
the regenerative actions of the hormone (Fig. 3).
Estradiol increases neurogenesis in the SVZ of adult male (Li et al.,
2011; Zheng et al., 2013; Table 2) and adult ovariectomized female
(Suzuki et al., 2009; Li et al., 2011; Cheng et al., 2013; Khan et al.,
2015; Table 2) rats and mice after brain ischemia and in diabetic mice
(Saravia et al., 2006). The hormone also increases neurogenesis in the
SGL of ovariectomized female mice and rats (Li et al., 2011; Cheng
et al., 2013) submitted to brain ischemia, in the SGL of diabetic mice
(Saravia et al., 2006) and in the SGL of rats with hypertensive en-
cephalopathy (Pietranera et al., 2015; Table 2). Althoigh both ERα and
ERβ are involved in the regulation of neurogenesis by estradiol, in
hypertensive rats the ERβ agonist DPN is more active in increasing
neurogenesis than the ERα agonist 4,4′,4″-(4-propyl-[1H]-pyrazole-
1,3,5-triyl)trisphenol (PPT) (Pietranera et al., 2016).
IGF-1 and BDNF, which are known to upregulate adult neurogenesis
in the rodent brain, may mediate the effects of estradiol on adult neu-
rogenesis under physiological conditions and after brain injury (Mendez
et al., 2006; Pietranera et al., 2016). In addition, in adult male rats
submitted to brain ischemia, estradiol post-stroke treatment induces an
increase in neurogenesis in the ischemic ipsilateral SVZ in parallel to an
increase in hypoxia-inducible factor 1α (HIF-1α) and vascular en-
dothelial growth factor (VEGF) (Zheng et al., 2013; Table 2). Since HIF-
1α is known to regulate neurogenesis by increasing the expression of
I. Azcoitia, et al. Frontiers in Neuroendocrinology xxx (xxxx) xxxx
11
(caption on next page)
I. Azcoitia, et al. Frontiers in Neuroendocrinology xxx (xxxx) xxxx
12
VEGF, the hormonal increase in the expression of these two factors after
brain ischemia may be involved in the effect of estradiol on post-is-
chemic neurogenesis.
4.2. Neuritogenesis, synaptogenesis and neuronal plasticity
In addition to enhance injury-induced neurogenesis, estradiol may
exert neuroprotective actions by promoting the reparation of the in-
jured neuronal circuits. Estradiol is known to promote neuritogenesis in
developing neurons (Arevalo et al., 2011) and also promotes axonal
repair after injury (Fig. 3). Thus, estradiol enhances axonal regenera-
tion in peripheral nerves (Acosta et al., 2017) and decreases moto-
neuron axonal loss and promotes motoneuron dendritic growth in the
central nervous system in animal models of spinal cord injury
(Sengelaub and Xu, 2018). Estradiol also decreases axonal loss in ex-
perimental autoimmune encephalomyelitis in rats. In this model of
multiple sclerosis, the neuroprotective actions of the hormone were
associated with the inhibition of ROCK (J. Feng et al., 2013), which is
known to participate in axonal growth and synaptic plasticity.
The role of estradiol from gonadal or neuronal origin in the reg-
ulation of synaptic plasticity is well established (Azcoitia et al., 2018).
This neuroplastic regulation may participate in the neuroprotective and
neuroreparative actions of the hormone. For instance, estradiol syn-
thesized by neuronal aromatase, promotes dendritic spine formation in
hippocampal pyramidal neurons in hippocampal slices, prevents spine
synapse loss induced by the blockade of GABAA receptors and increases
glutamate decarboxylase expression and GABA synthesis in hippo-
campal primary interneurons (Zhou et al., 2007). In the hippocampus,
estradiol enhances synaptic sprouting and the expression of the sy-
naptic protein synaptophysin in the molecular layer of the dentate
gyrus of ovariectomized female rats in response to entorhinal cortex
lesion (Stone et al., 1998). The synaptogenic effect of estradiol in this
model was mediated by apolipoprotein E (apoE), since the effect of the
hormone was lost in apoE KO mice (Stone et al., 1998). ApoE induction
by estradiol is involved in the promotion of neuritic growth by the
hormone in different in vitro and in vivo models (Struble et al., 2008).
Since apoE participates in cholesterol homeostasis and transports cho-
lesterol from astrocytes to neurons and since regulation of cholesterol
homeostasis may participate in the neuroprotective mechanisms of es-
tradiol (see Section 2.14), a possible role of cholesterol-mediated sy-
naptogenesis (Fester et al., 2009) on the neuroprotective actions of the
hormone can be postulated. Furthermore, since the ε4 allelic variant of
apoE is a major genetic risk factor for Alzheimer’s disease, the action of
estradiol on apoE regulation may be of particular relevance for the
hormonal reparative processes in this neurodegenerative condition.
The role of estradiol in the regulation of reactive synaptogenesis
under neurodegenerative conditions has also been analyzed in other
neuropathological models. In a model of hippocampal neurodegenera-
tion in ovariectomized female rats, induced by the intraperitoneal ad-
ministration of the neurotoxic trimethylin, the neuroprotective actions
of estradiol were associated with the upregulation of the expression of
genes involved in synaptogenesis, such as Bcl2, trkB, cadherin 2 and
cyclin-dependent-kinase-5 (Corvino et al., 2015; Table 2). However,
synaptogenesis was not directly assessed in this study and the upregu-
lated genes also participate in other cellular functions, including the
regulation of apoptosis. Nevertheless, the ERα selective agonist PPT
improves cognition and hippocampal synapse loss induced by long-term
ovariectomy in rats (Qu et al., 2013) and there is evidence that under
neurodegenerative conditions estradiol modulates the number of den-
dritic spines (Fig. 3), which are postsynaptic structures involved in
synaptic plasticity. For instance, the number of dendritic spines was
assessed in adult male rats exposed to bilateral common carotid artery
occlusion. In this model, estradiol enhances expression of synaptic
proteins, such as synaptophysin and PSD95 and increases the number of
dendritic spines in the CA1 hippocampal region (Zhu et al., 2017;
Table 2). Estradiol also increases the number of dendritic spines in the
ischemic cerebral cortex of adult ovariectomized female rats (Khan
et al., 2015; Table 2), in CA1 neurons in a model of chronic hy-
pertension (Pietranera et al., 2015; Table 2) and counteracts in adult
male hippocampus dendritic alterations caused in CA1 by perinatal
asphyxia, by a mechanism involving the PI3K/Akt/GSK3β signaling
pathway (Saraceno et al., 2018; Table 2).
4.3. Inhibition of excitotoxicity
Excitotoxicity is a common cause of cell death in neurodegenerative
diseases and mainly affects neurons and oligodendrocytes. High con-
centrations of extracellular glutamate result in the overstimulation of
AMPA, kainate and NMDA receptors in neurons (AMPA and kainate
receptors in oligodendrocytes). The overstimulation of these Ca2+
permeable receptors generates an increased influx of Ca2+ and, con-
sequently, a rise in intracellular Ca2+ concentration, which activates
calpain-mediated neuronal death. Ca2+ is also accumulated in mi-
tochondria and this result in mitochondrial depolarization, increased
production of oxygen free radicals, the activation of apoptotic signaling
and finally cell death by necrosis or apoptosis.
Estradiol may exert neuroprotective actions against excitotoxicity
(Azcoitia et al., 1998; Velísková, 2006) by several complementary
mechanisms (Fig. 3). One is the decrease of extracellular glutamate
levels. This is allowed by increasing glutamate uptake by astrocytes,
because the hormone increases the expression of glutamate transpor-
ters, such as glutamate transporter-1 (GLT-1) and the glutamate as-
partate transporter GLAST, in these cells (Lee et al., 2012; Acaz-Fonseca
et al., 2014; Karki et al., 2014; Table 1). Estradiol may also protect
neurons from excitotoxicity by inducing the release of protective factors
by astrocytes, such as GDNF, which has been shown to protect spinal
motoneurons from AMPA toxicity (Platania et al., 2005; Acaz-Fonseca
et al., 2014; Table 1).
In addition, estradiol regulates neuronal excitability and prevents
excitotoxicity and apoptosis by the control of intracellular Ca2+ levels
in neurons and astrocytes (Zhao and Brinton, 2007; Zup and Madden,
2016; Table 1; Fig. 3). Under basal conditions estradiol regulation of
Fig. 3. Subcellular, cellular and tissue events involved in the neuroprotective actions of estradiol. The molecular neuroprotective signaling mechanisms activated by
estradiol regulate different subcellular, cellular and tissue events that contribute to protect and repair the injured CNS. Estradiol facilitates injury-induced neuro-
genesis in the SGL of the adult hippocampus as well as in the lateral ventricles. The well-characterized neuritogenic effects of the hormone in vitro, promoting axonal
and dendritic growth, may be also of relevance for the reparation of damaged neuronal connectivity in vivo under pathological circumstances. The neuritogenic
actions of estradiol are complemented with the hormonal facilitation of spinogenesis and synaptogenesis after brain injury. In addition to promote tissue repair,
estradiol increases neuronal and glial cell survival by decreasing excitotoxicity and ROS-induced oxidative stress. Thus, the hormone reduces extracellular glutamate
levels and intraneuronal Ca2+ levels, protects mitochondrial membrane potential, decreases mitochondrial DNA damage, lipid and nucleic acid peroxidation and
caspase activation and promotes the expression of genes coding for antiapoptotic proteins, antioxidant enzymes and oxidative phosphorylation (OxPHOS) proteins. In
addition, estradiol decreases neuroinflammation by regulating the activity of glial cells involved in the inflammatory response and the infiltration of peripheral
immune cells in the CNS, such as pro-inflammatory and B-regulatory (B-reg) cells. Thus, the hormone (i), decreases the transcription of genes coding for pro-forms of
proinflammatory cytokines, the formation of inflammasomes and the production of active proinflammatory cytokines; (ii), promotes non-reactive phenotypes (M2-
like) in microglia and astrocytes and (iii), inhibits the infiltration of pro-inflammatory leukocytes and stimulates the infiltration of B-regulatory cells into the brain
parenchyma. Estradiol also promotes the survival of CNS cells by regulating autophagy and preventing an excessive autophagic activity under pathological con-
ditions. Finally, estradiol promotes myelin protection and remyelination.
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intracellular calcium signaling coordinates multiple physiological ac-
tions of the hormone (Zup and Madden, 2016). This regulation may be
associated with an increase in calcium uptake by neurons. For instance,
estradiol potentiates neuronal L-type Ca2+ channels in parallel to rapid
intracellular signaling to modulate synaptic plasticity and memory
(Zhao and Brinton, 2007). However, under pathological circumstances,
estradiol blocks the excessive rise in intracellular calcium as a protec-
tive mechanism. Thus, the hormone protects motoneurons from gluta-
mate-induced excitotoxicity by inhibiting L-type Ca2+ channels and
Ca2+ influx (Sribnick et al., 2009; Table 1). Estradiol and selective
estrogen receptor modulators (SERMs) have been also shown to inhibit
Ca2+ flux, preventing intracellular Ca2+ accumulation, through
TRPA1, TRPM2 and TRPV1, in neurons of ovariectomized rats (Yazğan
and Nazıroğlu, 2017; Table 2). Finally, estradiol may prevent ex-
citotoxicity by regulating the excitatory/inhibitory balance and pro-
tecting inhibitory neurons (see Section 5.1).
4.4. Mitochondrial protection and oxidative stress
A by-product of oxidative phosphorylation in the mitochondria is
the formation of reactive oxygen species (ROS). Under physiological
conditions the antioxidant system of the brain, composed by anti-
oxidant defense enzymes and small antioxidant molecules, prevents
mitochondrial nucleic acid, protein and lipid peroxidation by ROS.
However, the neural tissue, which has a high metabolic activity and is
rich in lipid content, is particularly vulnerable to oxidative stress. Thus,
under pathological conditions with high ROS production, such as brain
ischemia and other neurodegenerative insults and neurological dis-
orders, oxidative damage of neural tissue may result in the functional
impairment of neurons and glial cells. Uncontrolled oxidative stress
initiates a vicious circle in the brain tissue, causing mitochondrial
dysfunction that in turn provokes more oxidative stress. Finally, the
imbalance between ROS production and the expression of antioxidant
defense enzymes results in the induction of apoptosis.
Estradiol has been shown to decrease oxidative damage and lipid
peroxidation in neural cells in vitro (Nilsen, 2008; Liu et al., 2011; Guo
et al., 2012; Rettberg et al., 2014; Sørvik et al., 2018; Table 1) and in rat
models of hypoxia-ischemia, traumatic brain injury and Parkinson’s
disease (Zhang et al., 2009; Zhu et al., 2012; Aguirre-Vidal et al., 2017;
Lu et al., 2018). The antioxidant effect of the hormone is mediated by
the increase in the brain expression of oxidative stress response en-
zymes, such as catalase, glutathione peroxidase, superoxide dismutase
(SOD), peroxiredoxin 5 and glutaredoxin (Nilsen, 2008; Rettberg et al.,
2014). For instance, estradiol increases the expression of SOD1 and
decreases protein and DNA damage in brain slices exposed to oxygen
glucose deprivation, suggesting that SOD1, which decreases the mi-
tochondrial release of cytochrome c, may be involved in the protective
action of the hormone (Rao et al., 2011; Table 1). Estradiol has been
also shown to increase SOD1 and SOD2 immunoreactivity in the sub-
stantia nigra in the MPTP mouse model of Parkinson’s disease
(Tripanichkul et al., 2007; Table 2). Furthermore, the hormone in-
creases the expression of apurinic endonuclease, a protein involved in
DNA repair and redox regulation, in the cerebral cortex of ovar-
iectomized mice exposed to hypoxia (Dietrich et al., 2013).
The protective mechanisms activated by estradiol against oxidative
stress in the brain involve the protection of mitochondrial function
(Tables 1 and 2; Fig. 3). Mitochondria are affected by membrane and
nuclear initiated estradiol signaling and are also direct targets of es-
tradiol, since ERs are also located in the mitochondria (Simpkins et al.,
2010; Vasconsuelo et al., 2013; Rettberg et al., 2014). Estradiol reg-
ulates the expression of several mitochondrial genes, including genes
encoding for proteins of the mitochondria respiratory chain (Simpkins
et al., 2010; Vasconsuelo et al., 2013; Rettberg et al., 2014). The hor-
mone regulates the activity of the mitochondria respiratory chain
through ERβ (Vasconsuelo et al., 2013), although both ERα and ERβ are
involved in the actions of estradiol on mitochondrial function (Rettberg
et al., 2014). Thus, the hormone increases both mitochondrial re-
spiratory capacity (Yao et al., 2011) and ATP production (Guo et al.,
2010; Rettberg et al., 2014), maintains mitochondria membrane po-
tential (Simpkins et al., 2010; Guo et al., 2010, 2012), and reduces the
mitochondrial production of reactive oxygen species (Guo et al., 2010)
and the amount of oxidative damage to mitochondrial DNA (Nilsen,
2008) in neural cells exposed to different insults and reduces mi-
tochondrial dysfunction in cellular models of Alzheimer’s disease
(Grimm et al., 2016a).
4.5. Apoptosis
The mitochondria play a central role in the integration and activa-
tion of cell death signaling pathways. Therefore, the protective actions
of estradiol by regulating oxidative stress and preventing mitochondria
dysfunction result in a decrease in caspase activation and the inhibition
of apoptosis, which is a common final neuroprotective event in the
action of estradiol in numerous models of neural injury and neurode-
generation (Tables 1 and 2; Fig. 3). Thus estradiol prevents apoptosis in
neurons exposed to oxygen glucose deprivation (Chen et al., 2015; Guo
et al., 2017), H2O2 (Liu et al., 2011; De Marinis et al., 2013; Nuzzo
et al., 2017), glutamate (Sribnick et al., 2009), β-amyloid (Yao et al.,
2007) or neuroinflammatory molecules (Smith et al., 2009) and in
animal models of cerebral ischemia (Ma et al., 2016), traumatic brain
injury (Bao et al., 2011; Lu et al., 2018), spinal cord injury (Rong et al.,
2012) and retinal degeneration (Nixon and Simpkins, 2012), among
others. The protective action of estradiol not only involves the intrinsic
apoptotic pathway, since the hormone reduces Fas ligand expression
induced by transient global cerebral ischemia in the CA1 subfield of the
hippocampus of male rats (Wang et al., 2006) and inhibits Fas-mediated
apoptosis in the cerebral cortex of ovariectomized mice exposed to
middle cerebral artery occlusion (Jia et al., 2009).
The antiapoptotic action of estradiol is mediated by JNK inhibition
(see Section 2.4), followed by the upregulation of antiapoptotic pro-
teins, such as those of the Bcl-2 family members and survivin, and the
consequent inhibition of cytochrome c release by the mitochondria and
the activation of the caspase cascade. The upregulation of antiapoptotic
Bcl-2 family members in the brain is necessary for the neuroprotective
action of the hormone in different models of neurodegeneration
(Alkayed et al., 2001; D’Astous et al., 2006; Morissette et al., 2008;
Saraceno et al., 2018; Table 2) and it has been detected by numerous
laboratories. For instance, in vitro studies have shown that estradiol
increases the expression of Bcl-2 in mesencephalic organotypic cultures
(Wang et al., 2011; Table 1), hippocampal primary neurons (Zhao and
Brinton, 2007; Table 1) and spinal cord motoneurons (Cardona-
Rossinyol et al., 2013). In addition, the hormone upregulates Bcl-w in
primary cortical neurons exposed to β-amyloid (Yao et al., 2007). These
in vitro studies have also shown that the upregulation of antiapoptotic
molecules by estradiol is accompanied by the downregulation of
proapoptotic Bcl-2 family members, such as Bax (Wei et al., 2018;
Table 2) and Bim (Yao et al., 2007).
Studies in vivo have documented that estradiol counteracts the de-
crease in the expression of antiapoptotic Bcl-2 family members, Bcl-2
and Bcl-XL, and the decrease in Bcl-2/Bax ratio induced by ovariectomy
in the rat hypothalamus and hippocampus (Garcia-Segura et al., 1998;
Sharma and Mehra, 2008; Qu et al., 2013). In middle cerebral artery
occlusion stroke models, the hormone promotes Bcl-2 expression in
peri-infarct region of the female rat brain (Alkayed et al., 2001; Zhang
et al., 2017) and upregulates Bcl-2 expression in the brain of male rats
via the microRNA miR-375 (Herzog et al., 2017). Estradiol also in-
creases the Bcl-2/Bax ratio in the hippocampus of male rats exposed to
perinatal asphyxia (Saraceno et al., 2018; Table 2) and the Bcl-2/Bad
ratio in rodent models of Parkinson’s disease (D’Astous et al., 2006;
Morissette et al., 2008; Table 2).
In addition to Bcl-2 family proteins, another molecule regulated by
estradiol in the brain to prevent apoptosis and that mediates the
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neuroprotective effect of the hormone is survivin, a member of the
inhibitor-of-apoptosis family of proteins. For instance, estradiol in-
creases survivin expression in the hippocampus of female rats sub-
mitted to global cerebral ischemia (Zhang et al., 2008; Sehara et al.,
2013; Table 2) and in the pericontusional area in the brain of female
rats after traumatic brain injury (Bao et al., 2011; Table 2). Further-
more, the knockdown of survivin in the hippocampus blocks the neu-
roprotective action of estradiol (Sehara et al., 2013; Table 2).
4.6. Autophagy
Autophagy is a cellular process involved in the production of energy
under metabolic stress conditions and involves the recycling of da-
maged cell organelle and large macromolecules. Different stimuli, in-
cluding oxidative stress and mitochondrial dysfunction, induce the
formation of double-membrane structures that engulf the cellular ma-
terial to be degraded after fusion with lysosomes. These double-mem-
brane structures are known as autophagosomes. The formation and
degradation of autophagosomes is a dynamic process and an adequate
equilibrium in autophagy activity is necessary to maintain cell home-
ostasis.
Several of the signaling pathways and molecules regulated by es-
tradiol after brain injury are known to modulate autophagy. These in-
clude ERK, the PI3K/Akt/mTORC1 pathway, AMPK, JNK, IGF-1, BDNF,
CREB and Bcl-2. Indeed, recent studies have shown that estradiol reg-
ulates autophagy in different cell types, including cancer cells (Xiang
et al., 2018). As expected for the homeostatic role of estradiol, the
hormone increases or decreases autophagy, depending on the cellular
model and the physiological conditions. The possible role of autophagy
in the neuroprotective actions of estradiol has been explored in human
retinal pigment epithelial cells exposed to hydrogen peroxide (Wei
et al., 2018; Table 1) and in in vivo models of retinal injury (Wei et al.,
Table 2), spinal cord injury (Lin et al., 2016) and cerebral ischemia (Li
et al., 2017). In human retinal pigment epithelial cells estradiol reduces
ROS levels and promotes cell survival in parallel to an increase in au-
tophagosomes (Wei et al., 2018; Table 1). Protective effects of estradiol
in the in vivo models of spinal cord injury and cerebral ischemia are
associated with an inhibition of autophagy (Lin et al., 2016; Li et al.,
2017) (Fig. 3). The estradiol metabolite, 2-methoxyestradiol, also re-
duces neural injury and autophagy after global cerebral ischemia (Xin
et al., 2011). Further studies are necessary to determine the precise role
that autophagy regulation plays in the neuroprotective actions of es-
tradiol.
4.7. Neuroinflammation
Inflammation is a homeostatic mechanism that maintains tissue
integrity after infection or injury and that is activated in the nervous
system, as in other organs, under pathological circumstances. Although
inflammation of the nervous tissue, or neuroinflammation, is a re-
parative process, it contributes to enhance neural degeneration if it is
not properly controlled. Indeed, there is evidence that the mechanism
that regulate neuroinflammation are deteriorated with aging and under
chronic neurodegenerative pathologies and that this impairment in the
control of neuroinflammation contributes to increase neural damage
under these circumstances. Glial cells, mainly astrocytes and microglia
in the CNS, are the main cellular elements that participate in the neu-
roinflammatory response.
Control of neuroinflammation is a common protective mechanism of
estradiol in animal models of neurodegenerative diseases. This action of
estradiol has been detected in different models of neurodegeneration,
such as traumatic brain injury (López Rodríguez et al., 2011; Barreto
et al., 2014; Pedersen et al., 2018; Table 2), spinal cord injury
(Zendedel et al., 2018; Table 2), experimental autoimmune en-
cephalomyelitis (Benedek et al., 2016), Alzheimer’s disease (Vegeto
et al., 2006; Table 2) and brain ischemia (Pérez-Álvarez et al., 2012; de
Rivero Vaccari et al., 2016; Zhang et al., 2018).
Estradiol controls neuroinflammation by the regulation of NFκB
activity (see Section 2.9), reducing the reactive activation of astrocytes
(López Rodríguez et al., 2011; Pérez-Álvarez et al., 2012) and microglia
(Pérez-Álvarez et al., 2012; Arevalo et al., 2013; Habib et al., 2014) and
the downregulation of the expression of pro-inflammatory cytokines,
such as TNF-α, IL-1β and IL-6, in astrocytes and microglia (Vegeto
et al., 2006; Cerciat et al., 2010; Giraud et al., 2010; Arevalo et al.,
2013; Zhang et al., 2018) (see Tables 1 and 2). In addition to regulate
the activity of glial cells involved in the inflammatory response, estra-
diol also regulates the infiltration of peripheral immune cells in the CNS
(Fig. 3). Thus, the hormone prevents the infiltration of activated leu-
kocytes in the CNS, but promotes the infiltration of regulatory B cells
(Benedek et al., 2016).
The control of neuroinflammation by estradiol is exerted through
the regulation of inflammasomes, which are multiprotein cytoplasmic
complexes that play a central role in the activation of the inflammatory
response (Fig. 3). Several classes of inflammasomes have been de-
scribed in the nervous system, such as the NOD-, leucine-rich-repeats
and pyrin domain containing 3 (NLRP3) inflammasome. After activa-
tion, NLRP3 form oligomers and recruit apoptosis-associated speck-like
protein containing a caspase recruitment domain (ASC), an adaptor
protein that interacts with pro-caspase 1. Then caspase 1 is activated
and converts pro-forms of pro-inflammatory cytokines, such as pro-IL-
1β, in active forms, such as IL-1β (Heneka et al., 2018).
Estradiol has been shown to reduce inflammasome activation in
microglia in vitro (Slowik et al., 2018; Table 1), in the hippocampus of
ovariectomized rats and mice in vivo (Thakkar et al., 2016; Table 2) and
in the injured CNS in different models of neurodegeneration, including
models of amyotrophic lateral sclerosis in mouse (Heitzer et al., 2017)
and rat models of global cerebral ischemia (de Rivero Vaccari et al.,
2016) and spinal cord injury (Zendedel et al., 2018; Table 2). Func-
tional improvement induced by estradiol in these models are associated
with a reduced expression of several inflammasome components, in-
cluding ASC and NLRP3 (Thakkar et al., 2016; Heitzer et al., 2017;
Slowik et al., 2018; Zendedel et al., 2018), and of caspase-1 and
proinflammatory cytokines (Thakkar et al., 2016; de Rivero Vaccari
et al., 2016; Heitzer et al., 2017; Zendedel et al., 2018).
4.8. Myelin protection and remyelination
Myelin is essential for the proper propagation of action potentials
and therefore, for the normal function of the CNS. Myelin structure and
function are altered not only in demyelinating diseases, such as mul-
tiple sclerosis, but also in other CNS pathologies, such as traumatic
brain and spinal cord injuries, stroke, microvascular ischemic damage
and vascular dementia. White matter and myelin lesions are also a
frequent outcome of perinatal asphyxia and preterm birth and myelin
function is altered in psychiatric disorders and neurodegenerative dis-
eases, such as Parkinson’s and Alzheimer’s diseases. Myelin protection
and remyelination are, therefore, relevant components of the neuro-
protective actions of estradiol.
Estradiol protects myelin sheaths and myelinated axons in the CA1
hippocampal subfield (Xiao et al., 2018) and in the white matter of the
cerebral hemispheres (He et al., 2018) of ovariectomized middle-aged
rats. The hormone also prevents oligodendrocyte cell death induced by
peroxynitrite generator 3‐(4‐morpholinyl)‐sydnonimine (Takao et al.,
2004), hyperoxia (Gerstner et al., 2007) or oxygen/glucose deprivation
(Gerstner et al., 2007) and protects myelin sheaths and oligoden-
drocytes in the hippocampus of adult male rats exposed to bilateral
common artery occlusion (Zhu et al., 2017) and in the corpus callosum
of male mice in the cuprizone model of demyelination (Acs et al., 2009;
Taylor et al., 2010). Estradiol, in combination with progesterone, also
protects myelin in the mouse experimental autoimmune en-
cephalomyelitis model of multiple sclerosis (Garay et al., 2008).
The protective actions of estradiol on myelin are in part mediated by
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ERβ, as it has been shown by using selective ERβ agonists, such as DPN,
WAY-202041 and indazole-Cl, which also induce remyelination and
modulate the immune system in EAE models (Karim et al., 2019), and
in the cuprizone diet model of multiple sclerosis (Atkinson et al., 2019).
The remyelination mechanisms of ERβ ligands may be mediated by the
activation of the PI3K/Akt/mTOR signaling pathway (Kumar et al.,
2013).
5. Cell types involved in the neuroprotective and reparative
actions of estradiol
5.1. Excitatory and inhibitory neurons
Numerous studies on primary neuronal cultures and neuronal cell
lines have shown that estradiol exerts direct protective actions on
neurons. In vivo studies have shown that ERs are expressed in different
neuronal populations, including long distance projecting neurons and
interneurons. Therefore, acting on ERs estradiol may directly activate
protective mechanisms in neurons. Indeed, studies in vivo using neuron-
specific ERα KO mice have shown that the absence of this ER in neurons
impairs the neuroprotective action of estradiol in the MCAO model of
stroke (Elzer et al., 2010). Furthermore, the neuroprotection of hippo-
campal pyramidal neurons by estradiol in a model of global cerebral
ischemia is lost in parallel to a decrease in the expression of ERα in
these neurons induced by long-term estrogen deprivation in female rats
(Zhang et al., 2009).
The protective actions of estradiol on pyramidal neurons are well
characterized in different models of neurodegeneration, where the
hormone promotes synaptic connectivity (see Section 4.2), activates
neuroprotective signaling pathways and promotes the expression of
antiapoptotic molecules in these cells (Zhang et al., 2008; Sehara et al.,
2013; Table 2). In addition to the direct effects of estradiol on pyr-
amidal neurons, the protective actions of the hormone on these cells
may be also in part mediated by interneurons. It should be noted that
estradiol not only potentiates glutamatergic synaptic transmission but
also regulates the efficacy of synaptic inhibition.
Several lines of evidence indicate that interneurons participate in
the neuroprotective mechanisms of estradiol. In the kainic acid rat
model of excitotoxic injury, the hormone promotes the survival of so-
matostatin and neuropetide Y immunoreactive hilar interneurons in
ovariectomized rats (Azcoitia et al., 1998; Velísková, 2006; Table 2). In
another hippocampal model of neurodegeneration, the administration
of trimethylin to ovariectomized rats, estradiol increases the expression
of the interneuronal markers glutamic acid decarboxylase 67, neuro-
peptide Y and parvalbumin (Corvino et al., 2015; Table 2). Estradiol
also prevents the reduction in parvalbumin expression in ovar-
iectomized rats submitted to MCAO ischemic brain injury and in hip-
pocampal neuronal cultures exposed to glutamate (Koh, 2014). By
protecting interneurons, the hormone may contribute to maintain the
balance between excitation and inhibition, decreasing the excitotoxic
damage of neurons and oligodendrocytes under pathological condi-
tions.
5.2. Oligodendrocytes
Oligodendrocytes provide metabolic support for neuronal cell
bodies and axonal processes, release different neurotrophic factors to
regulate neuronal function and generate the myelin sheaths that cover
myelinated axons in the white matter, which are essential for saltatory
conduction of action potentials. In the human brain, white matter loss is
a key component in the functional deficits caused by stroke and de-
myelinated diseases, such as multiple sclerosis. Oligodendrocytes have
a high metabolic rate and are very sensitive to metabolic stress, oxi-
dative stress and mitochondrial injury. Oligodendrocytes and pro-
liferating oligodendrocyte precursor cells are also susceptible to ex-
citotoxic cell death and are affected by inflammatory cytokines and
cytotoxic T-lymphocytes. Therefore, the antioxidant activity of estra-
diol, the homeostatic actions of the hormone on mitochondria, the
hormonal prevention of excitotoxicity and the estrogenic anti-in-
flammatory actions on astrocytes and microglia may be highly relevant
for the protection of oligodendrocytes under different pathological
conditions.
The neuroprotective actions of estradiol in the white matter (see
Section 4.8) may be in part mediated by actions of the hormone in other
cell types, such as astrocytes, microglia and infiltrating inflammatory
cells (Spence et al., 2013; Benedek et al., 2016; Pansiot et al., 2016;
Table 2). However, estradiol directly acts on ERs expressed by oligo-
dendrocytes, such as ERα, ERβ and GPER (Takao et al., 2004; Hirahara
et al., 2009, 2013; Khalaj et al., 2016) and activate neuroprotective
signaling, such as ERK and the PI3K/Akt/GSK3 and mTOR signaling
pathways in these cells (Hirahara et al., 2009; Kumar et al., 2013;
Khalaj et al., 2016). A direct proof for the implication of oligoden-
drocytes in the neuroprotective actions of estrogen receptors has been
obtained in experimental autoimmune encephalomyelitis, where these
cells mediate endogenous myelination and functional recovery stimu-
lated by the ERβ agonist DPN (Khalaj et al., 2016).
5.3. Astrocytes
Astrocytes play an essential role in the maintenance of brain tissue
homeostasis. They contribute to the control of cerebral blood flow, the
function of blood brain barrier and the composition of the extracellular
milieu, keeping the necessary environment for the proper function of
neurons and other glial cells. Their role in the modulation of neuronal
metabolism, by providing neurons with nutrients, such as lactate, and
neurotrophic factors is well characterized. In addition, astrocytes
modulate neuronal excitability by regulating the extracellular con-
centration of ions, such as K+, and neurotransmitters, such as gluta-
mate. Furthermore, they participate in synaptic function, expressing
receptors for neurotransmitters and releasing molecules (glio-
transmitters) that regulate synaptic transmission, and convey informa-
tion between different synapses through glial dynamic networks con-
nected by gap junctions.
Astrocytes participate in brain plasticity under physiological and
pathological conditions, being involved in adult neurogenesis, sy-
naptogenesis, synaptic plasticity, myelin formation and the repair of the
damaged neural tissue after injury. Under neurodegenerative condi-
tions, astrocytes acquire a reactive phenotype, are involved in the in-
flammatory response and contribute to decrease excitotoxic cell death
of neurons and oligodendrocytes by decreasing extracellular glutamate
levels and by releasing neurotrophic factors.
Estradiol regulates the activity of astrocytes under physiological and
pathological conditions (Acaz-Fonseca et al., 2016). These cells are
direct targets of the hormone, expressing ERα, ERβ and GPER (Acaz-
Fonseca et al., 2016). In addition, the expression of ERs in astrocytes is
upregulated under conditions of brain injury (Acaz-Fonseca et al.,
2014) and it has been shown that ERs expressed in astrocytes mediate
the activation of neuroprotective mechanisms elicited by estradiol in
different models of brain pathology. Depending on the model, the im-
plication of ERα (Bains et al., 2007; Spence et al., 2013), ERβ (Ma et al.,
2016) and GPER (Lee et al., 2012) expressed in astrocytes in the neu-
roprotective actions of the hormone has been documented. For in-
stance, deletion of ERα in astrocytes prevents the neuroprotective ac-
tion of estradiol in experimental autoimmune encephalomyelitis
(Spence et al., 2013; Table 2). ERα expressed in astrocytes also med-
iates neuroprotective actions of estradiol on dopaminergic neurons in
mesencephalic cultures treated with MPP(+) (Bains et al., 2007), while
ERβ expressed by astrocytes mediates the neuroprotective action of
estradiol against brain ischemia (Ma et al., 2016) and GPER is involved
in the regulation of glutamate transporter in astrocytes (Lee et al., 2012;
Table 1).
Under pathological conditions estradiol elicits different responses in
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astrocytes that contribute to neuroprotection (Table 1). Thus, the hor-
mone decreases gliosis, reducing the number of reactive astrocytes in
brain injured regions (Barreto et al., 2009; López Rodríguez et al., 2011;
Table 2), the activation of NFκB in these cells and their expression of
proinflammatory molecules (Cerciat et al., 2010; Giraud et al., 2010; De
Marinis et al., 2013). In addition, estradiol promotes the release of
different factors by astrocytes, such as GDNF, TGF-β1, TGF-β2, IGF-1,
VEGF, ApoE and neuroglobin, which protect neurons from ex-
citotoxicity, hypoxia-ischemia, 6-OHDA toxicity, β-amyloid neurotoxi-
city and other neurotoxic insults (Sortino et al., 2004; Dhandapani
et al., 2005; Platania et al., 2005; De Marinis et al., 2013; Acaz-Fonseca
et al., 2014; Sohrabji, 2015; Table 1). In addition, astrocytes mediate
estrogenic actions in the control of blood brain barrier under neuroin-
flammatory conditions and in the regulation of cerebral edema after
ischemia, at least in part by the regulation of the expression of aqua-
porin 4 in perivascular astrocytes (Acaz-Fonseca et al., 2014) and
participate in the neuroprotective actions of the hormone against ex-
citotoxicity by decreasing extracellular glutamate levels (Lee et al.,
2012; Acaz-Fonseca et al., 2014; Karki et al., 2014; Table 1). Estradiol
also exerts direct protective actions on astrocytes, increasing glucose
transport, improving mitochondrial function and decreasing oxidative
stress and oxidative cell death (Rettberg et al., 2014; Guo et al., 2012;
Table 1). Finally, reactive astrocytes are a source of endogenous es-
tradiol, which exerts neuroprotective actions after brain injury (see
Section 3).
5.4. Brain capillary endothelial cells and blood brain barrier
The blood brain barrier (BBB) regulates the entry of ions, molecules
and cells into the brain parenchyma and is composed by capillary en-
dothelial cells, the associated basal lamina, pericytes and endfeet pro-
cesses from astrocytes. Brain capillary endothelial cells have specific
structural properties, such as lack of fenestrations and the presence of
highly organized tight and adherens junctions, that contribute to the
maintenance of the barrier, together with the expression of specific
receptors and transporter systems that allow the selective bidirectional
transcytosis of molecules to be transported through the barrier. In ad-
dition, astrocytes and pericytes release different molecules that con-
tribute to develop and maintain barrier properties of brain capillary
endothelial cells during physiological and pathological conditions.
Furthermore, astrocytic endfeet express channels, transporters and re-
ceptors that contribute to barrier selectivity.
BBB dysfunction and increased permeability is associated with
aging and it also occurs in different neurological disorders. Estradiol
controls BBB function and this action may be highly relevant for its
neuroprotective mechanisms. For instance, estradiol attenuates BBB
disruption and decreases leakiness and brain edema induced by brain
ischemic injury, traumatic brain injury, spinal cord injury and other
insults and protects against tight junction disruption in brain capillary
endothelial cells subjected to oxygen glucose deprivation/reperfusion
injury (Na et al., 2015; Sohrabji, 2015; Table 1). These effects are
mediated by direct protective actions of estradiol on brain capillary
endothelial cells (Guo et al., 2010) and by indirect actions on astrocytes
and microglia, decreasing inflammation and oxidative stress. In addi-
tion, estradiol enhances brain angiogenesis, contributing to tissue re-
pair after stroke (Sohrabji, 2015).
5.5. Microglia
In contrast to astrocytes, which have an ectodermal origin, micro-
glia derive from a pool of yolk sac derived macrophages that enter the
brain during development. Microglia are the main players in the in-
itiation and resolution of the immune response in the CNS. Under
resting conditions, they scan the tissue environment and become acti-
vated by the presence of pathogens or injured cells. Then, microglial
cells migrate towards the injured site to restore tissue homeostasis by
the coordinated release of pro-inflammatory and anti-inflammatory
molecules and by phagocyting infectious agents, cellular debris and
damaged cells. In addition, the phagocytic activity of microglia parti-
cipates in the physiological remodeling of neural tissue during neuro-
genesis, synaptogenesis and synaptic plasticity.
Although the activation of microglia is aimed to repair the damaged
tissue, in chronic neurodegenerative diseases and psychiatric disorders
microglia may present functional abnormalities that impair their re-
storative function. Under these conditions, they may contribute to in-
crease neural tissue damage. Microglial cells may also present a se-
nescent phenotype in aged brains, being unable to properly respond to
damage signals and contributing to tissue deterioration. Estradiol reg-
ulates microglia activation (Table 2), promoting the acquisition of re-
parative phenotypes (M2-like) by these cells (Arevalo et al., 2013)
(Fig. 3). Thus, the hormone promotes protective responses of microglia
and decreases microglia reactivity in experimental models of multiple
sclerosis (Benedek et al., 2016), amyotrophic lateral sclerosis (Heitzer
et al., 2017) stroke (Pérez-Álvarez et al., 2012; Habib et al., 2014;
Slowik et al., 2018; Zhang et al., 2018), traumatic brain injury (Barreto
et al., 2014; Table 2), spinal cord injury (Zendedel et al., 2018; Table 2)
or Alzheimer’s disease (Vegeto et al., 2006; Table 2), among others
(Arevalo et al., 2013). By regulating the inflammatory response and the
reactive molecular phenotype of microglia, estradiol protects other
cellular components of the CNS, such as oligodendrocytes, neurons and
the blood brain barrier.
6. Sex differences in the neuroprotective actions of estradiol:
Cellular and molecular mechanisms
6.1. Sex differences in the neuroprotective action of estradiol
In the previous sections we have analyzed the neuroprotective ac-
tions of estradiol regardless to sex, although many of the reviewed
studies have been performed in female animals. It is important to
consider, however, that the neuroprotective action of estradiol may be
different in males and females. It is well known that most pathological
alterations of the nervous system present sex differences in the in-
cidence, prevalence, age of onset, progression, severity and/or response
to medication (Melcangi et al., 2016). Sex differences in the response to
estradiol in different models of brain pathology have been also reported
(Gillies, and McArthur, 2010a; Giatti et al., 2018). For instance, cir-
culating estradiol promotes neuroprotection from striatal lesions in fe-
males but has no effect or a deleterious action in males (Bourque et al.,
2011; Gillies and McArthur, 2010b). In contrast, in a Parkinson model
induced by 6-hydroxydopamine injections in the substantia nigra, AC-
186, an ERβ ligand, prevents motor, sensorimotor, and cognitive defi-
cits and reduces loss of dopaminergic neurons in male rats, but not in
females (McFarland et al., 2013). Furthermore, estradiol is protective
against experimental stroke in older male mice but losses its neuro-
protective potency in older female mice (F. Liu et al., 2012).
6.2. Participation of estrogen signaling in the generation of sex differences in
the neuroprotective actions of estradiol
Sex differences in the distribution of ERs (Bourque et al., 2011),
together with a different role of ER subtypes in brain plasticity, neu-
roprotection and repair in male and female neurons (Bryant and Dorsa,
2010; W. Wang et al., 2018) may participate in the generation of sex
differences in the neuroprotective actions of estradiol. In addition, there
are differences in ER signaling in the brain of males and females
(Tabatadze et al., 2015; Oberlander and Woolley, 2016; Koss et al.,
2018; Jain et al., 2019; Meitzen et al., 2019; Zafer et al., 2019), which
are in part mediated by epigenetic modifications in ER encoding genes
(Schwarz et al., 2010; Giatti et al., 2018) and micro RNAs (Giatti et al.,
2018) and are also dependent on sexually differentiated interactions
with the signaling mechanisms of other neuroprotective factors, such as
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BDNF (Scharfman and MacLusky, 2014), IGF-1 (Munive et al., 2016) or
the endocannabinoid system (Tabatadze et al., 2015), which in turn
also present sex differences in the brain. All these sexually differ-
entiated molecular mechanisms cause different responses to estradiol in
the brain of male and female animals (Tabatadze et al., 2015; Munive
et al., 2016; Koss et al., 2018) and may determine sex differences in the
neuroprotective actions of the hormone.
6.3. Subcellular and cellular contributions to sex differences in the
neuroprotective actions of estradiol
Functional sex differences in brain subcellular organelle, including
the mitochondria (Acaz-Fonseca et al., 2017; Gaignard et al., 2018;
Giatti et al., 2018), or in the action of sex hormones on these organelle
(Grimm et al., 2016b), may also contribute to divergent neuroprotec-
tive outcomes of estrogen therapy. For instance, mitochondria con-
tribute to sex differences in oxidative stress under neurodegenerative
conditions (Ruszkiewicz et al., 2019) and may generate sex differences
in the neuroprotective actions of estradiol.
The different neuroprotective action of estradiol in male and female
animals may be also partially determined by the sex dimorphic struc-
tural and functional organization of specific neuronal circuits (Gillies
and McArthur, 2010b) and by sex differences in neuronal function and
plasticity in response to the hormone (Hyer et al., 2018; Krentzel and
Meitzen, 2018). In these sex differences also participate the associated
glial cells. Indeed, sex differences in the function of astrocytes, oligo-
dendrocytes and microglia have been reported (Cerghet et al., 2009;
Acaz-Fonseca et al., 2016; Kodama and Gan, 2019), including sex dif-
ferences in phagocytic and migratory activity of microglia (Nelson
et al., 2017; Yanguas-Casás et al., 2018; VanRyzin et al., 2019), which
may potentially contribute to different reparative processes after injury
in male and female brains. In addition, estradiol activates different
neuroprotective mechanisms in male and female glial cells (Acaz-
Fonseca et al., 2016; Stary et al., 2017; Table 1), which may therefore
contribute to the generation of sex differences in the response of CNS
tissue to injury and in the protective and reparative actions of the
hormone, modulating neuroinflammation, excitotoxicity, remyelina-
tion, cerebral blood flow, blood brain barrier integrity and edema for-
mation (Section 5).
6.4. Contribution of brain-derived estradiol to sex differences in
neuroprotection
Another potential source of sex differences in the neuroprotective
effects of the pharmacological administration of estradiol is the differ-
ence in the endogenous basal levels of the hormone in males and fe-
males. Estradiol levels present sex differences not only in plasma, but
also in the CNS (Barker and Galea, 2009), allowing, therefore, a sex
dimorphic interactions of endogenous and exogenous estradiol in the
activation of ER signaling in brain tissue.
Sex differences in the brain estradiol levels partially reflect the
differences in plasma, but are largely determined by its local synthesis
and metabolism (Caruso et al., 2013; Hojo and Kawato, 2018). Brain
estradiol synthesis generates sex differences in neurogenesis, synaptic
plasticity and behavior (Bowers et al., 2010; Bender et al., 2017;
Borbélyová et al., 2017; Brocca and Garcia-Segura, 2018; Kokras et al.,
2018; Shay et al., 2018; Brandt and Rune, 2019) and, as it has been
discussed in Section 3, contributes to the activation of neuroprotective
mechanisms after CNS injury.
There are several possible levels of interaction of pharmacologically
administered estradiol with locally produced estradiol in neuroprotec-
tion. From one side, pharmacological administration of estradiol up-
regulates brain aromatase expression in the brain under neurodegen-
erative conditions (Pietranera et al., 2015; Table 2). On the other hand,
local brain estradiol synthesis may influence the neuroprotective out-
come of peripheral estradiol and of pharmacological estrogen therapy.
Some studies suggest that estradiol synthesis in the brain is not only an
endogenous mechanism of neuroprotection but it is also essential for
the neuroprotective action of plasma estradiol or estradiol therapies.
Thus, in H19-7 hippocampal cells, the inhibition of aromatase prevents
the neuroprotective action of exogenous estradiol (Chamniansawat and
Chongthammakun, 2012). In addition, the neuroprotective action of
circulating estradiol in a mouse model of Alzheimer's disease is sig-
nificantly reduced in aromatase KO female mice that have undetectable
levels of brain estradiol (Li et al., 2013). It may be postulated that since
estradiol exerts a positive-feedback action on the expression of brain
aromatase and ERα in neurons, aromatase induction after brain injury
may initiate a cycle that potentiates in parallel brain estradiol synthesis
and the neuroprotective signaling of estradiol originated in both local
and peripheral sources. However, this hypothesis needs experimental
confirmation.
6.5. Sex chromosome effects in the neuroprotective actions of estradiol
The use of the four core genotypes mouse model, in which sex
chromosome complement is unrelated to gonadal sex, has shown that
sex differences in brain structure are the result of an interplay between
the sex chromosome complement and the pre- and post-pubertal action
of gonadal hormones (Cambiasso et al., 2017; Vousden et al., 2018).
Such an interplay between sex chromosome genes and gonadal hor-
mones may also determine sex differences in mood disorders (Seney
et al., 2013), in the outcome of stroke in aged mice (McCullough et al.,
2016) and in the remyelination of the corpus callosum in a mouse
model of demyelination (Moore et al., 2013) and may explain the
higher pathology in males and the higher susceptibility of females to
multiple sclerosis. Thus, in the EAE mouse model of multiple sclerosis, a
XY complement in the CNS determines an increased pathology com-
pared to CNS XX animals (Du et al., 2014). In addition, the sex chro-
mosome complement determines a higher expression of the X chro-
mosome gene Kdm6a in XX animals. This gene codes for a histone
demethylase that escapes X inactivation and its deletion in CD4+ T
cells protects mice from EAE. Therefore, the higher expression of
Kdm6a in females may contribute to their higher susceptibility for
multiple sclerosis (Itoh et al., 2019).
The studies with the four core genotypes mouse model also suggest
that sex differences in the immune system that are determined by sex
chromosome complement may influence the manifestation of sex dif-
ferences in brain pathology. Thus, in addition to the mentioned effects
of sex differences in the expression of Kdm6a in CD4+ T cells in the
susceptibility to EAE (Itoh et al., 2019), increased levels of proin-
flammatory cytokines may contribute to the higher brain infarct size
and the higher microglia activation observed in male and female XX
mice, compared to male and female XY mice, after middle cerebral
artery occlusion (McCullough et al., 2016).
The interaction between the sex chromosome complement and go-
nadal hormones also determines the expression of aromatase and es-
trogen receptors (Cisternas et al., 2015, 2017; Cambiasso et al., 2017)
in the brain and, therefore, may contribute to the different effects of
estrogen therapy in males and females. However, this possibility needs
to be experimentally explored. Thus, further studies should determine
whether the interaction of sex chromosome complement and the en-
dogenous levels of estradiol influence the neuroprotective actions of
estrogen therapy in different models of brain pathology.
7. Conclusions and perspectives
The studies reviewed here show that estradiol activates multiple
molecular and cellular mechanisms that act in concert to promote
neural protection and repair after acute CNS injuries and chronic neu-
rodegenerative conditions. Different molecular protective mechanisms
activated by the hormone in a single neural cell converge to promote
survival of this individual cell by the regulation of intracellular events,
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such as mitochondrial activity, antioxidant capacity, autophagy and
apoptosis. In addition, the neuroprotective mechanisms activated by
estradiol in one cell type will impact on other cells. For instance, the
action of estradiol on astrocytes (Section 5.3), decreasing uptake of
extracellular glutamate by these cells, prevents the excitotoxic effects of
the excess of this neurotransmitter on neurons and oligodendrocytes
(Section 4.3). The transcriptional control of neurotrophic factors and
inflammatory molecules exerted by estradiol on astrocytes and micro-
glia also impact on the survival of other cell types, on the function of
blood-brain barrier (Section 5.4), on myelin integrity (Section 4.8) and
on the regeneration of damaged neuronal circuits (Section 4.2). In a
similar way, the estrogenic protection of interneurons (Section 5.1)
contributes to maintain the excitation/inhibition balance, which is es-
sential to maintain the homeostasis of all cell types in the CNS. Further
research is needed to systematically determine the role of the different
neuronal and glial populations in different brain regions and patholo-
gical conditions in the neuroprotective actions of estradiol. In addition
to classical forms of cell to cell communication, it is also necessary to
explore in detail the role of miRNAs and extracellular vesicles in the
integration of the neuroprotective responses of different cell types and
CNS regions in response to estradiol.
In the present paper we have limited our focus to the discussion of
molecular, cellular and tissue neuroprotective events elicited by estra-
diol within the CNS. However, it is essential to consider that the neu-
roprotective mechanisms that are directly activated in the CNS by es-
tradiol, are exerted in an organism also primed by the hormone.
Estradiol receptors are expressed in different tissues and organs, such as
the bone, skeletal muscle, hearth, skin, liver, kidney, pancreas, gas-
trointestinal tract and the adipose tissue. Thus, estradiol exerts a per-
ipheral control of the immune, endocrine, metabolic, cardiovascular
and locomotor systems. These peripheral actions of estradiol, pro-
moting general body health, may also contribute to neuroprotection.
For instance, the estrogenic regulation of peripheral immune responses
(Morales et al., 2006; Karim et al., 2018) may impact on the protective
actions of the hormone on autoimmune demyelinating diseases; the
estrogenic regulation of adiposity and peripheral body metabolism
(Rettberg et al., 2014) may improve brain bioenergetics; and the es-
trogenic signaling on peripheral organs may induce the release of
tissue-specific cytokines with neuroprotective actions. Estradiol also
affects gut microbiome composition (Kaliannan et al., 2018), which in
turn may change the microbiota-gut-brain axis communication under
brain neurodegenerative conditions. On the other hand, estrogenic ef-
fects in brain regions involved in the control of glucose and lipid me-
tabolism, food intake, energy balance, temperature, blood pressure,
respiration and other autonomic functions (Xu and López, 2018), par-
ticipate in the maintenance of body homeostasis under pathological
conditions. Also, estradiol actions on brain regions controlling mood,
motivation, motor control and locomotor activity, contribute to in-
crease physical activity (Xu et al., 2015) and may potentially improve
the bioenergetics of skeletal muscles, which in turn, has positive effects
for brain health and cognition. Therefore, the protective actions of es-
tradiol in the CNS cannot be dissociated from the protective actions of
the hormone in the other parts of the body. This is particularly relevant
when considering the outcomes of estrogen therapy in postmenopausal
women. Thus, in future research we need to implement new mechan-
istic approaches to unravel the details of brain-body interactions in
estrogenic neuroprotection.
An important question that needs to be explored more system-
atically is the role of sex differences in the neuroprotective actions of
estradiol. Although estradiol has been shown to be neuroprotective in
both sexes, there is evidence that, at least for some pathological models,
the hormonal effect may diverge in males and females. As previously
discussed, one of the causes of this may be possible sex differences in
estradiol synthesis or metabolism within the CNS. However, new stu-
dies are necessary to validate this possibility; for instance, using animal
models with selective modifications in the expression and/or activity of
aromatase in specific brain regions. Brain estradiol synthesis may be
particularly relevant in women after the abrupt fall in plasma estradiol
levels with menopause. The importance of aromatase and estradiol
signaling for women healthy brain function is suggested by the iden-
tification of several variants of the genes encoding for aromatase and
ERs that increase the risk of AD, specifically in women (Fernández-
Martinez et al., 2013; Medway et al., 2014). However, the precise role
of brain estradiol synthesis and signaling on brain healthy aging, in men
and women, needs to be adequately investigated.
The analysis of the molecular mechanisms activated by estradiol to
promote neuroprotection reveals a high level of complexity, including
the interaction of estradiol signaling with the signaling activated by
other factors. However, it is unknown whether the activation of this
complex signaling is a general phenomenon under all pathological
conditions and CNS regions or presents some degree of selectivity. In
particular, it is unclear whether all these signaling mechanisms operate
in a similar way in both sexes. Thus, we cannot exclude possible dif-
ferences in estradiol neuroprotective signaling between males and fe-
males that would also contribute the sex differences in the outcome of
estrogenic therapy. However, this possibility remains basically un-
explored. The complexity of the estrogenic signaling mechanisms re-
viewed in this paper also predicts that alterations in some of its com-
ponents with aging or under pathological conditions may impair the
neuroprotective action of the hormone. Some studies in animal models
have revealed the downregulation of ERα in the hippocampus with
aging (Scott et al., 2012), suggesting that age may impair the neuro-
protective action of estradiol. In addition, aging and brain pathology
may also affect other components of estrogen neuroprotective sig-
naling. For instance, plasma levels of IGF-1, which as we have discussed
in this paper is a factor interacting with estradiol neuroprotective sig-
naling, are decreased with aging and are altered under different neu-
rological conditions in humans (Busiguina et al., 2000). In addition, a
dissociation of the molecular interactions of ERs and IGF-1 receptors in
caveolae has been detected in the brain of AD patients, suggesting an
altered estradiol signaling in this pathology (Canerina-Amaro et al.,
2017). The implications of such an impairment of estrogen neuropro-
tective signaling for the cognitive outcome of estrogen therapy in
postmenopausal women are obvious. Therefore, new research is ne-
cessary to fully identify the components of estradiol signaling that are
affected by aging or brain disease and new estrogenic therapeutic ap-
proaches should take in consideration this information.
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